Cancer evidence library
Liver Cancer
PubMed-indexed evidence for primary liver cancer, especially hepatocellular carcinoma.
PubMed only
Research ranked
Conflicts shown
Data downloadable
Alexandria collection
Liver Cancer
Living medical evidence library
Cataloguing in progress
The evidence engine has not built this synopsis yet.
The topic exists in Alexandria’s catalog. Run its PubMed evidence pipeline to retrieve, parse, extract, cluster, and publish the first deterministic snapshot.
R
Complete Ranked PubMed Index
The retrieval-priority score orders records using publication type, recency, sample-size signals, and replication signals. It is not a recommendation or a formal risk-of-bias grade.
Current Standard Of Care60 records
Rank110.0
Clinical guideline or consensus statement
Hepatology international · 2026 · PMID 42365189
Globally, especially in the Asia Pacific region, chronic hepatitis B infection has led to an undesirable escalating morbidity and mortality with acute-on chronic liver failure, end-staged liver cirrhosis, and hepatocellular carcinoma. This has happened despite the past four decades of major scientific advances made in screening methods, vaccination strategies, highly effective low-cost anti-viral therapies, and surveillance strategies for early detection of hepatocellular carcinoma. To address this health threat, A…
Rank110.0
Clinical guideline or consensus statementCorrection flagged
The Lancet. Haematology · 2026 · PMID 42069412
Autosomal dominant acute porphyrias are rare inherited disorders of haem biosynthesis characterised by accumulation of potentially neurotoxic porphyrin precursors and attacks of severe abdominal pain with autonomic and neuropsychiatric features. Disease severity ranges from asymptomatic individuals to those with recurrent, life-threatening attacks. The International Porphyria Network invited 34 acute porphyria specialists from 17 countries to form an expert panel. The invited group included clinicians from diverse …
Rank110.0
Clinical guideline or consensus statement
Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2026 · PMID 42615769
BACKGROUND: Hepatocellular carcinoma is a major cause of cancer-related mortality and represents a growing public health challenge.
AIMS: To develop multidisciplinary evidence-based recommendations for the prevention and early detection of hepatocellular carcinoma.
METHODS: This consensus was coordinated by the Brazilian Society of Surgical Oncology, with the participation of 13 additional national societies. A steering committee defined the key clinical questions addressing prevention, surveillance, and early dete…
Rank110.0
Clinical guideline or consensus statement
Gastroenterologia y hepatologia · 2026 · PMID 42061813
The hepatitis delta virus (HDV), whose infection depends on the presence of the hepatitis B virus (HBV), is associated with one of the chronic viral hepatitis that most rapidly progresses to advanced liver disease, including liver cirrhosis and/or hepatocellular carcinoma. In this context, screening for HBV/HDV infection is key to the early diagnosis of hepatitis D, improving the prognosis of infected individuals through a strategy that has proven to be effective and efficient. This document reviews the epidemiolog…
Rank110.0
Clinical guideline or consensus statement
Journal of gastroenterology · 2026 · PMID 42120590
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, with an increasing number of patients progressing to cirrhosis and hepatocellular carcinoma (HCC). Early identification of individuals at high risk for advanced fibrosis is essential for preventing liver-related events and improving long-term outcomes. This guideline summarizes current evidence and provides practical recommendations for the diagnosis, risk stratification, and managemen…
Rank110.0
Clinical guideline or consensus statement
Gastroenterology · 2026 · PMID 42017860
DESCRIPTION: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death in patients with cirrhosis. Although advancements in surgical, locoregional, and systemic therapies have improved outcomes for patients with early-stage HCC, most cases are diagnosed at later stages due to both the limitations of currently recommended surveillance modalities and their underuse, with fewer than 1 in 4 patients with cirrhosis receiving surveillance for this tumor. Current guidelines recommend semiannual surveillanc…
Rank110.0
Clinical guideline or consensus statement
ESMO open · 2026 · PMID 42660571
The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment, and follow-up of patients with hepatocellular carcinoma (HCC) were published in May 2025 and were adapted in August 2025, according to previously established standard methodology, to produce the Pan-Asian adapted ESMO consensus guidelines for the management of Asian patients with HCC. The adapted guidelines presented in this manuscript are the consensus opinions reached by a panel of Asian experts in the trea…
Rank110.0
Clinical guideline or consensus statement
Hepatology (Baltimore, Md.) · 2026 · PMID 41405234
BACKGROUND AND AIMS: Liver transplant is a specialized treatment for a spectrum of indications that use a scarce resource. Transplant is guided by principles of justice, equity, and benefit, with a constant conflict between competing interests. Organs are a national resource with a goal of equitable distribution across sites. An AASLD guideline for the evaluation and selection of appropriate candidates for transplant has been available since 2005.
METHODS: A multidisciplinary writing group of liver transplant exper…
Rank109.2
Systematic review or meta-analysis
Alimentary pharmacology & therapeutics · 2026 · PMID 41882492
BACKGROUND: Cirrhosis is the irreversible architectural endpoint of chronic liver disease and is the greatest risk factor for hepatocellular carcinoma (HCC). Despite its centrality in HCC management algorithms, there are no standardised morphologic criteria for diagnosing cirrhosis on cross-sectional imaging. Criteria used in clinical studies and clinical practice guidelines have not been reviewed systematically. We aim to assess cross-sectional imaging criteria in clinical practice guidelines and clinical studies.…
Rank107.0
Systematic review or meta-analysis
Medicine · 2026 · PMID 42299577
BACKGROUND: Beyond surgical intervention, hepatocellular carcinoma is mainly treated with 3 main approaches: transarterial chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC) as local treatment, immune checkpoint inhibitors (ICIs), and tyrosine kinase inhibitors (TKIs). Up to now, clinical experts have not reached a consistent consensus on how to reasonably select combination therapy. Therefore, we performed this research to contrast the clinical outcomes of local treatment plus ICIs and TKIs …
Rank103.0
Systematic review or meta-analysis
BMC gastroenterology · 2026 · PMID 42157114
BACKGROUND: Hepatocellular carcinoma (HCC) is characterized by high mortality, frequent recurrence, and limited long-term benefit from systemic therapy and radiotherapy. Circular RNAs (circRNAs), a class of covalently closed non-coding RNAs with high molecular stability and tissue-specific expression, have emerged as important regulators of HCC biology and treatment response.
METHODS: We searched PubMed from database inception to May 2, 2026 and manually screened the reference lists of eligible studies and relevant…
Rank102.0
Systematic review or meta-analysisResult signal: harm
JHEP reports : innovation in hepatology · 2026 · PMID 42250763
BACKGROUND & AIMS: The rs738409C>G polymorphism in the patatin-like phospholipase domain-containing protein 3 gene (PNPLA3 I148M variant) contributes to the largest fraction of metabolic dysfunction-associated steatotic liver disease (MASLD) heritability. However, its prognostic impact on long-term clinical outcomes related to MASLD remains incompletely characterized. We performed a meta-analysis of observational studies to quantify the impact of PNPLA3 polymorphisms on the risk of developing hepatic and extrahepat…
Rank98.2
Systematic review or meta-analysis
Medicine · 2026 · PMID 42536554
BACKGROUND: This study aimed to summarize and grade the existing evidence on continuous hepatic artery infusion chemotherapy (HAIC) arterial drug administration and catheter care, providing evidence-based guidance for clinical nursing decisions.
METHODS: Using the "6S" pyramid model, We searched 10 electronic resources (UpToDate, Joanna Briggs Institute [JBI], Cochrane Library, Web of Science, Embase, PubMed, EBSCOhost Research Platform, China National Knowledge Infrastructure, Wanfang, and SinoMed) and 5 professio…
Rank98.0
Systematic review or meta-analysis
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42629496
PURPOSE: Oxaliplatin is widely used to treat gastrointestinal and hepatobiliary cancers, yet hypersensitivity reactions (HSRs) remain a significant safety concern in oncology. Although international guidelines address anaphylaxis and chemotherapy-related HSRs, existing recommendations are fragmented and often lack specificity for oxaliplatin or for hepatic arterial infusion chemotherapy (HAIC), for which evidence is limited. This study aimed to retrieve and synthesize the best available evidence to support standard…
Rank96.0
Systematic review or meta-analysis
Ultrasound in medicine & biology · 2026 · PMID 42471281
OBJECTIVE: Ultrasound fusion imaging is a hybrid technique that combines real-time ultrasonography (US) with pre-acquired computed tomography (CT) or magnetic resonance imaging (MRI), using electromagnetic (EM) tracking to enable precise spatial correlation between modalities. This technology is increasingly used for liver imaging and interventions, especially when conventional B-mode US fails to provide adequate lesion visualization. The aim of this technical review and position statement is to evaluate the techni…
Rank73.0
Multicenter clinical study
International journal of clinical oncology · 2026 · PMID 42062697
BACKGROUND: Trifluridine/Tipiracil (FTD/TPI) combined with bevacizumab (Bev) is a standard treatment for patients with unresectable metastatic colorectal cancer (mCRC) in later-line therapy. Despite the availability of other drugs like regorafenib and fruquintinib, there is no consensus on the optimal treatment choice or sequence for later-line therapies due to a lack of clearly defined prognostic indicators. This multicenter real-world analysis aimed to identify predictive factors related to the effectiveness of F…
Rank63.6
Observational or cohort study
Investigative radiology · 2026 · PMID 41140290
OBJECTIVES: To explore magnetic resonance imaging (MRI) and gallium-68 ( 68 Ga)-DOTATATE positron emission tomography (PET) performance in the assessment of neuroendocrine liver metastases (NELMs) on a per-lesion basis, with particular attention to the contribution of individual MRI sequences and assessment of other factors that might influence their detection.
MATERIALS AND METHODS: This observational retrospective study included patients with histologically confirmed neuroendocrine tumors who underwent both contr…
Rank52.5
Other PubMed-indexed publication
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2026 · PMID 42173286
Intrahepatic cholangiocarcinoma (iCCA) is a molecularly heterogeneous liver cancer with a poor prognosis. Improved stratification is needed to guide postoperative therapy. In this study, we applied integrative multiomics analysis to classify iCCA and identify biomarkers predictive of adjuvant treatment benefit. Using publicly available datasets (including whole exome sequencing, RNA sequencing, proteomics, and phosphoproteomics from FU-iCCA cohort and a transcriptomic cohort GSE244807), we defined 3 robust molecula…
Rank51.1
Other PubMed-indexed publication
British journal of cancer · 2026 · PMID 41992059
BACKGROUND: Liver surveillance imaging is essential for detecting early asymptomatic metastases in uveal melanoma, which predominantly involves the liver. Early detection may improve treatment opportunities, but variability in imaging protocols and a lack of consensus on surveillance duration present challenges. This study aimed to evaluate our systemic surveillance protocol, optimise pathways, and assess risk factors for metastasis.
METHODS: We retrospectively analysed patients diagnosed with uveal melanoma betwee…
Rank50.6
Other PubMed-indexed publication
AJR. American journal of roentgenology · 2026 · PMID 41562458
BACKGROUND. The LI-RADS version 2018 (v2018) diagnostic algorithm prioritizes an enhancing capsule differently from other major features. The role of an enhancing capsule in hepatocellular carcinoma (HCC) diagnosis remains uncertain, particularly for CT. OBJECTIVE. The purpose of this study was to compare the diagnostic performance of CT for diagnosis of HCC using original LI-RADS v2018 criteria for LR-5 versus modified LR-5 criteria that treat an enhancing capsule the same as other major features. METHODS. This re…
Rank50.5
Other PubMed-indexed publication
European radiology experimental · 2026 · PMID 42201507
OBJECTIVE: There is still a lack of widely applicable biomarkers for immunotherapy in hepatocellular carcinoma (HCC). We aim to identify subtypes using computed tomography (CT) imaging features of HCC and assess their value in predicting prognosis and the effectiveness of immunotherapy.
MATERIALS AND METHODS: We used unsupervised consensus clustering based on quantitative contrast-enhanced CT features to identify imaging subtypes and investigated their value in predicting prognosis and the effectiveness of immunoth…
Rank50.0
Other PubMed-indexed publication
Radiographics : a review publication of the Radiological Society of North America, Inc · 2026 · PMID 42658729
Management of hepatocellular carcinoma (HCC) can vary substantially by region. The authors highlight differences between Eastern and Western health care systems in the use of MRI for surveillance, diagnosis, and treatment monitoring in patients with HCC. These regional differences reflect variations in disease prevalence, treatment practice patterns, and reimbursement policies as well as the evolving role of MRI in the care continuum, for which global consensus has not yet been achieved. Although variations are not…
Rank49.8
Other PubMed-indexed publication
Radiology · 2026 · PMID 42227857
Background Liver Imaging Reporting and Data System (LI-RADS) Nonradiation Treatment Response Algorithm (TRA) version 2024 (v2024) was recently introduced following version 2017 (v2017) to standardize the assessment of hepatocellular carcinoma (HCC) after nonradiation local-regional therapy (LRT). However, a comparison of their accuracy across imaging modalities has not yet been performed. Purpose To compare the diagnostic accuracy of LI-RADS Nonradiation TRA v2024 with that of LI-RADS TRA v2017 for assessing HCC vi…
Rank49.5
Other PubMed-indexed publicationResult signal: null
Academic radiology · 2026 · PMID 41807162
RATIONALE AND OBJECTIVES: This retrospective study compared thermal ablation (TA) and surgical resection (SR) in treating hepatocellular carcinoma (HCC) based on multiparametric gadoxetic acid-enhanced MRI features, with an emphasis on the impact of tumor location, size, and liver function reserve.
MATERIALS AND METHODS: Patients with early-stage HCC treated with either TA or SR at our hospital from January 2016 to August 2021 were included. Propensity score matching (PSM) with a 1:1 nearest-neighbor algorithm was …
Rank49.4
Other PubMed-indexed publication
Annals of surgical oncology · 2026 · PMID 41721163
BACKGROUND: Adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TIL) is an FDA-approved treatment for metastatic melanoma and continues to be studied in other cancers. As a common site of metastatic disease, the liver is potentially a useful site for TIL procurement, but only if the procedures can be performed with an acceptably low risk of complications.
METHODS: A retrospective analysis was performed on 158 patients who underwent liver resection for TIL procurement between 2000 and 2024. Patients had …
Diagnosis And Screening297 records
Rank110.0
Clinical guideline or consensus statement
Gastroenterologia y hepatologia · 2026 · PMID 42061813
The hepatitis delta virus (HDV), whose infection depends on the presence of the hepatitis B virus (HBV), is associated with one of the chronic viral hepatitis that most rapidly progresses to advanced liver disease, including liver cirrhosis and/or hepatocellular carcinoma. In this context, screening for HBV/HDV infection is key to the early diagnosis of hepatitis D, improving the prognosis of infected individuals through a strategy that has proven to be effective and efficient. This document reviews the epidemiolog…
Rank106.4
Systematic review or meta-analysis
Abdominal radiology (New York) · 2026 · PMID 41706100
BACKGROUND: The LI-RADS diagnostic algorithm uses imaging features in contrast-enhanced ultrasound (CEUS) to standardize the diagnosis of hepatocellular carcinoma (HCC) in at-risk patients. However, the diagnostic performance of specific major feature combinations has not been comprehensively evaluated.
PURPOSE: To evaluate the diagnostic performance of CEUS LI-RADs version 2017 major feature combinations for (HCC) in at-risk individuals across LI-RADS categories 3-5.
MATERIALS AND METHODS: A living systematic revi…
Rank105.4
Systematic review or meta-analysis
European journal of radiology · 2026 · PMID 42167003
OBJECTIVE: To evaluate the diagnostic performance of magnetic resonance imaging (MRI)-based artificial intelligence (AI) models in preoperatively predicting hepatocellular carcinoma (HCC) histological grade.
METHODS: We conducted this systematic review and meta-analysis in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses of Diagnostic Test Accuracy (PRISMA-DTA) guidelines. PubMed, Embase, and Web of Science were searched from inception to 10 February 2026. Bivariate random-effe…
Rank101.8
Systematic review or meta-analysis
Journal of magnetic resonance imaging : JMRI · 2026 · PMID 42563623
BACKGROUND: The Liver Imaging Reporting and Data System (LI-RADS) is a classification system to diagnose hepatocellular carcinoma (HCC) noninvasively. The reported LI-RADS inter-reader variability in single-center studies highlights the need to better understand the variability on a broader scale.
PURPOSE: Evaluate inter-reader agreement for LI-RADS CT/MRI v2018 categorization and imaging features using individual participant data (IPD) meta-analysis for MRI and CT separately.
STUDY TYPE: Retrospective meta-analysi…
Rank101.0
Systematic review or meta-analysis
Journal of gastrointestinal cancer · 2026 · PMID 42536112
BACKGROUND: Primary hepatic angiosarcoma (PHA) is the most common primary malignant mesenchymal tumour of the liver in adults, accounting for only 0.1-2% of all primary hepatic malignancies. It carries a median overall survival of 6-9 months, driven by aggressive biology, non-specific presentation, and almost universal late-stage diagnosis. No disease-specific tumour markers, pathognomonic imaging features, or PHA-exclusive prospective trials exist.
METHODS: A comprehensive narrative review was performed using PubM…
Rank100.0
Systematic review or meta-analysis
Clinica chimica acta; international journal of clinical chemistry · 2026 · PMID 42248317
BACKGROUND: Exosomal microRNAs (miRNAs) have emerged as promising non-invasive biomarkers for hepatocellular carcinoma (HCC). Nevertheless, the overall diagnostic performance of exosomal miRNAs in HCC was still less reported. Therefore, this meta-analysis aimed to systematically assess the pooled diagnostic efficacy of exosomal miRNAs for HCC.
METHODS: A literature search was performed in accordance with the PRISMA guidelines, utilizing the PubMed, Web of Science, EMBASE, and CNKI databases up to December 22, 2024.…
Rank100.0
Systematic review or meta-analysisResult signal: null
Abdominal radiology (New York) · 2026 · PMID 41483152
PURPOSE: Differentiating hepatocellular adenoma (HCA) from malignant focal liver lesions (FLLs), including hepatocellular carcinoma (HCC), and metastases, is challenging yet clinically important. Given biopsy-associated bleeding risks in suspected HCA and differing treatment strategies, accurate noninvasive imaging biomarkers are needed.
METHODS: A systematic literature search of PubMed, Embase, Web of Science, and Cochrane Library up to August 10, 2025, identified studies reporting quantitative apparent diffusion …
Rank98.3
Randomized controlled trial
Cancer prevention research (Philadelphia, Pa.) · 2026 · PMID 42310898
UNLABELLED: Hepatocellular carcinoma (HCC) is a lethal cancer with an increasing burden. Few clinical trials have evaluated preventive strategies for HCC in high-risk patients with liver cirrhosis. Observational studies show that statins are associated with a reduced HCC risk although a causal link has yet to be established. This multicenter randomized double-blinded, placebo-controlled phase II trial of 40 mg/day oral simvastatin to reduce the likelihood of hepatocarcinogenesis was conducted at four sites in the U…
Rank96.0
Systematic review or meta-analysis
Clinical and translational radiation oncology · 2026 · PMID 42471954
Stereotactic body radiotherapy (SBRT) is an established locoregional treatment option for hepatocellular carcinoma (HCC). However, post-treatment imaging remains challenging because tumor response and focal liver reaction (FLR), defined as radiation-related alterations of the adjacent liver parenchyma, may both evolve gradually and mimic viable or recurrent tumor. We conducted a scoping review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PR…
Rank96.0
Systematic review or meta-analysis
Carcinogenesis · 2026 · PMID 42548278
Androgen receptor splice variant 7 (AR-V7) is associated with resistance to androgen receptor-targeting therapies in prostate cancer, but its prevalence and clinical relevance in non-prostatic cancers remain incompletely characterized. A systematic review was conducted in accordance with PRISMA guidelines. Thirty-four studies, including 4855 clinical cases and 60 cell lines, were included. Overall, AR-V7 positivity was reported in 948/4855 clinical cases (19.5%); however, this represents a descriptive estimate acro…
Rank92.0
Randomized controlled trial
BMJ open · 2026 · PMID 42586727
INTRODUCTION: Recognising and acting on the connection to Country as a determinant of Indigenous peoples' well-being is necessary to improve health inequities. Indigenous Australians experience a greater burden of chronic liver disease and poorer outcomes due to ongoing impacts of colonisation across determinants of health. This is exacerbated by a gradient in health outcomes based on remoteness, lack of specialist healthcare services and barriers to access. Our research aims to explore better ways to provide chron…
Rank89.2
Randomized clinical study
BMJ open · 2026 · PMID 42493202
INTRODUCTION: Liver resection is a technically demanding procedure due to the complex and highly variable anatomy of the liver. Conventional preoperative planning relies on two-dimensional imaging, which requires mental reconstruction of three-dimensional anatomical relationships and may increase cognitive workload and intraoperative decision-making time. Patient-specific three-dimensional (3D) liver mapping has been shown to improve anatomical understanding and planning accuracy; however its impact on intraoperati…
Rank89.1
Randomized clinical studyResult signal: benefit
Journal of integrative and complementary medicine · 2026 · PMID 42578431
BACKGROUND: This study was designed to assess the safety and preliminary efficacy of Sanshimao (SSM) formula in early and intermediate hepatocellular carcinoma (HCC) patients with cirrhosis.
METHODS: We conducted a prospective randomized, open-label, controlled trial, assigning early and intermediate HCC patients with cirrhosis in a 1:1 ratio to either the control group or the SSM group. Patients were followed for a 16-month treatment period. Patients in the SSM group received additional SSM formula in addition to …
Rank81.5
Multicenter clinical studyResult signal: harm
American journal of ophthalmology · 2026 · PMID 42229563
PURPOSE: Understanding how the risk of immune checkpoint inhibitor (ICI)-associated noninfectious uveitis (NIU) differs by malignancy and drug class may help understand its pathophysiology and guide targeted ophthalmic surveillance. This study aims to evaluate the comparative risk of ICI-associated NIU across different malignancies and drug classes.
DESIGN: Retrospective, multicenter clinical cohort study.
SUBJECTS: Adults with metastatic melanoma, lung cancer, renal cell carcinoma (RCC), urothelial carcinoma, hepa…
Rank81.0
Multicenter clinical study
Abdominal radiology (New York) · 2026 · PMID 41557182
OBJECTIVE: To compare the effect of different segmentation strategies on the performance of multiparametric MRI-based radiomics models for predicting response to combined therapy in unresectable hepatocellular carcinoma (HCC).
METHODS: This multicenter retrospective study included 334 patients with HCC from five tertiary hospitals between January 2021 and January 2025. Clinical data and pre-treatment MRI were collected for all eligible patients. Tumor regions of interest (ROIs) were automatically segmented using a …
Rank81.0
Multicenter clinical study
Alimentary pharmacology & therapeutics · 2026 · PMID 42017265
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) exhibits marked heterogeneity in fibrosis progression and liver-related outcomes. Liver biopsy is not feasible for longitudinal risk stratification at scale, creating a need for validated non-invasive biomarkers, particularly imaging biomarkers, that can predict clinically meaningful disease progression and liver-related outcomes.
AIMS: To describe the design and rationale of the GOLDMINE study, established to determine whether non-invasiv…
Rank80.5
Multicenter clinical study
European journal of radiology · 2026 · PMID 42229038
OBJECTIVES: To investigate the association between baseline body composition and objective response to first-line bevacizumab-based chemotherapy in patients with unresectable colorectal liver metastases (CRLM), and to develop a model for response prediction in this treatment setting.
METHODS: This multicenter retrospective cohort included 185 patients with newly diagnosed unresectable CRLM from three hospitals who received first-line bevacizumab therapy. Pre-treatment body composition parameters were quantified at …
Rank80.1
Phase II clinical trial
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2026 · PMID 42385524
AIMS: It is controversial whether monotherapy with immunotherapeutics is effective in early-stage hepatocellular carcinoma (HCC). We evaluated immunotherapy monotherapy as an initial neoadjuvant strategy.
METHODS: This prospective, single-arm, phase II trial of an adaptive neoadjuvant strategy enrolled patients with resectable, early-stage HCC. All patients received tislelizumab monotherapy; non-responders received subsequent lenvatinib combination therapy preoperatively.
RESULTS: For the overall efficacy of all 36…
Rank79.8
Multicenter clinical study
Hepatology (Baltimore, Md.) · 2026 · PMID 41746634
BACKGROUND AND AIMS: Pathological complete response (pCR) following conversion therapy for initially unresectable hepatocellular carcinoma (uHCC) remains challenging to predict preoperatively. This study developed and validated a model integrating clinicopathological and radiomic features of the tumor to predict pCR.
METHODS: In this multicenter retrospective study, temporal radiomics features were extracted from baseline, post-treatment, and delta (change) MRIs. Serum AFP response was calculated as log₁₀(preoperat…
Rank79.8
Multicenter clinical study
European radiology · 2026 · PMID 42053592
OBJECTIVES: Transarterial chemoembolization (TACE) is a promising locoregional therapy for unresectable colorectal liver metastases, but patient selection remains challenging. We aimed to develop and validate prognostic radiomics-based machine learning models in a multicenter, prospectively collected drug-eluting microsphere TACE cohort.
MATERIALS AND METHODS: We retrospectively analyzed 76 patients (176 lesions) from the prospective CIREL registry trial. Radiomic features were extracted from each lesion. We tested…
Rank78.5
Multicenter clinical study
Liver international : official journal of the International Association for the Study of the Liver · 2026 · PMID 42500825
BACKGROUND AND AIMS: Microvascular invasion (MVI) is a major determinant of postoperative recurrence and poor prognosis in hepatocellular carcinoma (HCC), yet MVI cannot be reliably identified before surgery: pathologic evaluation is invasive, prone to sampling bias, and available only after resection. We aimed to develop and evaluate a preoperative radiomics biomarker for noninvasive MVI prediction and postoperative risk stratification of recurrence-free survival.
METHODS: In this retrospective multicenter study, …
Rank78.2
Multicenter clinical study
European journal of radiology · 2026 · PMID 42320144
OBJECTIVES: To investigate the diagnostic performance of the quantitative morphological feature of solidity in preoperative prediction of proliferative hepatocellular carcinoma (HCC), and to compare the diagnostic performance between quantitative morphological features and machine learning (ML) models that incorporate Sonazoid contrast-enhanced ultrasound (CEUS) and clinical features.
METHODS: This retrospective two-center study included 395 patients with histopathologically confirmed HCC. The morphological feature…
Rank78.0
Multicenter clinical studyResult signal: null
European journal of radiology · 2026 · PMID 42150387
OBJECTIVE: To develop and validate radiomics models based on gadoxetate disodium (Gd-EOB-DTPA)-enhanced MRI for preoperative prediction of proliferative small hepatocellular carcinoma (sHCC) and to evaluate their prognostic value.
METHODS: A total of 331 patients with pathologically confirmed sHCC from two institutions were retrospectively enrolled and divided into training (n = 147), internal validation (n = 63), external validation (n = 59), and exploratory validation (n = 62) cohorts. Independent predictors were…
Rank77.7
Multicenter clinical study
BMJ open · 2026 · PMID 42486514
INTRODUCTION: Hepatocellular carcinoma is the sixth most common malignancy worldwide, with immune checkpoint inhibitors transforming treatment paradigms despite modest response rates of approximately 30%. Emotional distress, encompassing depression and anxiety symptoms, affects 30-50% of cancer patients and may influence immunotherapy efficacy through immune system modulation. Recent studies in lung cancer, gastric cancer and melanoma demonstrate associations between pretreatment emotional distress and worse immuno…
Rank76.9
Multicenter clinical study
Radiology · 2026 · PMID 42550027
Background With the advent of immune checkpoint inhibitor-based combination therapy, treatment sequencing for advanced hepatocellular carcinoma (HCC) has become increasingly complex. The Barcelona Clinic Liver Cancer (BCLC) 2026 recommendations emphasize individualized decision-making. Purpose To compare clinical outcomes of hepatic arterial infusion chemotherapy (HAIC) and tyrosine kinase inhibitors (TKIs) in patients with advanced HCC after atezolizumab-bevacizumab (AB) failure, within the BCLC 2026 treatment par…
Evidence Syntheses60 records
Rank110.9
Systematic review or meta-analysis
Critical reviews in oncology/hematology · 2026 · PMID 42314880
UNLABELLED: Management of liver tumors in children is well-defined, with clear treatment protocols established by organizations such as the International Society of Pediatric Oncology-Liver group (SIOPEL), the Children's Oncology Group (COG), and the Japanese Study Group for Pediatric Liver Tumors (JPLT). However, no structured approach exists for hilar lymph node (LN) resection. Surgical practices vary among centers, reflecting the adult setting. This systematic review aims to examine the current evidence on hilar…
Rank110.0
Systematic review or meta-analysis
Journal of viral hepatitis · 2026 · PMID 42605247
Liver cancer is the second leading cause of premature cancer mortality globally, whose main causes-HBV, HCV, MASH and alcohol use-are preventable. Viral hepatitis' carcinogenicity is not as well-known as the risk of lung cancer from smoking, leading to rising rates of liver cancer worldwide. The aim of this study was to compare the risk of liver cancer in HBV, HCV, HDV, MASH and alcohol consumption with the better-known risk of lung cancer associated with smoking. We extracted the relative risk of liver cancer from…
Rank110.0
Clinical guideline or consensus statement
ESMO open · 2026 · PMID 42660571
The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment, and follow-up of patients with hepatocellular carcinoma (HCC) were published in May 2025 and were adapted in August 2025, according to previously established standard methodology, to produce the Pan-Asian adapted ESMO consensus guidelines for the management of Asian patients with HCC. The adapted guidelines presented in this manuscript are the consensus opinions reached by a panel of Asian experts in the trea…
Rank110.0
Clinical guideline or consensus statement
Hepatology international · 2026 · PMID 42365189
Globally, especially in the Asia Pacific region, chronic hepatitis B infection has led to an undesirable escalating morbidity and mortality with acute-on chronic liver failure, end-staged liver cirrhosis, and hepatocellular carcinoma. This has happened despite the past four decades of major scientific advances made in screening methods, vaccination strategies, highly effective low-cost anti-viral therapies, and surveillance strategies for early detection of hepatocellular carcinoma. To address this health threat, A…
Rank110.0
Systematic review or meta-analysis
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2026 · PMID 42285810
BACKGROUND AND AIMS: Statins have been proposed as hepatoprotective agents in chronic liver disease (CLD); however, evidence from existing systematic reviews-including observational studies and clinical trials-is inconsistent and affected by substantial overlap. We conducted an umbrella review to synthesize the available evidence on the associations between statin use and hepatological outcomes in CLD patients, while addressing study overlap.
DESIGN: PubMed, EMBASE, and Cochrane Library were searched up to Septembe…
Rank110.0
Clinical guideline or consensus statement
Gastroenterologia y hepatologia · 2026 · PMID 42061813
The hepatitis delta virus (HDV), whose infection depends on the presence of the hepatitis B virus (HBV), is associated with one of the chronic viral hepatitis that most rapidly progresses to advanced liver disease, including liver cirrhosis and/or hepatocellular carcinoma. In this context, screening for HBV/HDV infection is key to the early diagnosis of hepatitis D, improving the prognosis of infected individuals through a strategy that has proven to be effective and efficient. This document reviews the epidemiolog…
Rank110.0
Clinical guideline or consensus statement
Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2026 · PMID 42615769
BACKGROUND: Hepatocellular carcinoma is a major cause of cancer-related mortality and represents a growing public health challenge.
AIMS: To develop multidisciplinary evidence-based recommendations for the prevention and early detection of hepatocellular carcinoma.
METHODS: This consensus was coordinated by the Brazilian Society of Surgical Oncology, with the participation of 13 additional national societies. A steering committee defined the key clinical questions addressing prevention, surveillance, and early dete…
Rank110.0
Systematic review or meta-analysisResult signal: harm
Hepatology communications · 2026 · PMID 42623525
BACKGROUND: Alcohol-associated liver disease (ALD) is a leading cause of advanced liver disease and liver transplantation worldwide. Cardiometabolic risk factors (CMRFs) may worsen ALD prognosis. While recent nomenclature acknowledges the impact of CMRFs in steatotic liver disease with low-to-moderate alcohol use, individuals with high alcohol intake are still classified as having ALD regardless of CMRF status. We conducted a systematic review to evaluate the impact of CMRFs, primarily diabetes, obesity, and metabo…
Rank109.7
Systematic review or meta-analysis
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2026 · PMID 42314305
BACKGROUND: Multidisciplinary team (MDT) management is widely endorsed for complex hepatobiliary and pancreatic (HBP) malignancies. However, robust systematic evidence evaluating its survival benefits and heterogeneity across distinct anatomical sites remains limited.
METHODS: Our study systematically searched four databases from their inception through Dec 17, 2025, for studies comparing MDT versus non-MDT care in HBP malignancies. The primary outcome was overall survival or mortality risk. Secondary outcomes incl…
Rank108.4
Systematic review or meta-analysis
European journal of gastroenterology & hepatology · 2026 · PMID 41604560
Hepatic failure is a potentially fatal complication in hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE). However, there is a lack of clear predictive factors for hepatic failure after TACE in HCC patients. This study aimed to identify all available data and determine the risk factors associated with hepatic failure after TACE in HCC patients. A systematic review and meta-analysis included 9 studies with a total of 1654 patients. The results showed that factors significantly …
Rank108.2
Systematic review or meta-analysis
AJR. American journal of roentgenology · 2026 · PMID 42018773
BACKGROUND. In LI-RADS CT/MRI version 2018 (v2018), ancillary features (AFs) support observation characterization and category assignment. The literature is lacking regarding interreader agreement on a broad range of AFs. OBJECTIVE. The purpose of the present study was to conduct a systematic review and meta-analysis of the interreader agreement for all individual AFs in LI-RADS CT/MRI v2018 and to identify factors associated with interpretation variability. EVIDENCE ACQUISITION. The MEDLINE, Embase, and Cochrane d…
Rank108.0
Systematic review or meta-analysis
Frontiers in immunology · 2026 · PMID 42620506
BACKGROUND: Phase III trials of first-line immunotherapy-based combinations for advanced hepatocellular carcinoma (HCC) have yielded heterogeneous results, and head-to-head comparisons remain scarce. We evaluated mechanism-based strategy classes and individual regimens using a dual-level Bayesian network meta-analysis to provide a structured interpretation of the current evidence.
METHODS: We systematically searched the literature up to December 28, 2025, and identified 15 phase III randomised controlled trials. A …
Rank108.0
Systematic review or meta-analysis
Clinical and translational gastroenterology · 2026 · PMID 42242200
INTRODUCTION: Gastrointestinal (GI) cancers account for a quarter of all cancers and one-third of cancer-related deaths worldwide. Novel diagnostic approaches are crucial to enhance early detection and improve patient outcomes. This review systematically identified and evaluated novel GI cancer detection approaches.
METHODS: A systematic review was conducted using PubMed, EMBASE, Scopus, and the Cochrane Library on December 11, 2024, and updated on June 2, 2025. Cohort studies and randomized controlled studies, pub…
Rank107.9
Systematic review or meta-analysis
JHEP reports : innovation in hepatology · 2026 · PMID 42167508
BACKGROUND & AIMS: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) is not routinely recommended for hepatocellular carcinoma (HCC) diagnosis or surveillance, and its prognostic role in patients with HCC remains unclear. This meta-analysis aims to evaluate the prognostic significance of 18F-FDG PET/CT in HCC.
METHODS: A systematic literature search was conducted until August 2024 to identify studies evaluating the prognostic value of 18F-FDG PET/CT in patients with HCC. Studi…
Rank107.9
Systematic review or meta-analysisResult signal: null
Journal of surgical oncology · 2026 · PMID 42296400
BACKGROUND: This present systematic review and meta-analysis aims to compare overall survival (OS), disease-free survival (DFS), morbidity and mortality outcomes in patients undergoing colorectal first (CRf) versus liver first (Lf) resections with synchronous colorectal liver metastases.
METHODOLOGY: A literature search was performed in PubMed, Cochrane Central trials register, and Google Scholar databases. This was conducted in line with current PRISMA guidelines. 95% confidence intervals were calculated for the p…
Rank107.7
Systematic review or meta-analysis
Journal of robotic surgery · 2026 · PMID 42717141
Repeat hepatectomy is a potentially curative treatment for selected patients with recurrent liver malignancies but is technically demanding because of adhesions, distorted anatomy, and limited operative working space. Robotic platforms may help address some of these challenges, but evidence on robotic repeat hepatectomy (RRH) is limited. This study critically reviews comparative perioperative evidence and repeat-hepatectomy-specific technical strategies. This review was performed in accordance with the PRISMA 2020 …
Rank107.7
Systematic review or meta-analysis
Journal of medical imaging and radiation oncology · 2026 · PMID 41918240
BACKGROUND: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, particularly among patients with chronic liver disease and cirrhosis. Non-contrast magnetic resonance imaging (NC-MRI) has emerged as a potential alternative imaging modality for HCC surveillance and diagnosis, avoiding the risks associated with contrast agents; however, its diagnostic performance has not been fully established. This systematic review and meta-analysis aimed to evaluate the diagnostic accuracy of NC…
Rank106.8
Systematic review or meta-analysis
World journal of surgery · 2026 · PMID 42281307
BACKGROUND: Laparoscopic liver resection (LLR) for posterosuperior (PS) segments remains technically challenging. Prior meta-analyses comparing LLR to open liver resection (OLR) often incorporated unmatched retrospective data, introducing severe selection bias, and predated recent randomized controlled trials (RCTs). This systematic review and meta-analysis evaluates the safety, short-term recovery, and oncological efficacy of LLR versus OLR specifically for parenchymal-preserving liver resection in PS segments (Co…
Rank106.5
Systematic review or meta-analysis
Journal of visualized experiments : JoVE · 2026 · PMID 42644535
This study aimed to evaluate the diagnostic value of radiomic features in predicting Ki-67 expression levels in hepatocellular carcinoma (HCC) through a meta-analysis. Electronic databases, including PubMed, Web of Science, the Cochrane Library, and Embase, were systematically searched for relevant clinical studies published through 20 August 2025. Studies using radiomic features to predict Ki-67 expression levels in patients with HCC were included. Sensitivity, specificity, and summary receiver operating character…
Rank106.4
Systematic review or meta-analysis
Abdominal radiology (New York) · 2026 · PMID 41706100
BACKGROUND: The LI-RADS diagnostic algorithm uses imaging features in contrast-enhanced ultrasound (CEUS) to standardize the diagnosis of hepatocellular carcinoma (HCC) in at-risk patients. However, the diagnostic performance of specific major feature combinations has not been comprehensively evaluated.
PURPOSE: To evaluate the diagnostic performance of CEUS LI-RADs version 2017 major feature combinations for (HCC) in at-risk individuals across LI-RADS categories 3-5.
MATERIALS AND METHODS: A living systematic revi…
Rank106.4
Systematic review or meta-analysis
JHEP reports : innovation in hepatology · 2026 · PMID 42128139
BACKGROUND: The efficacy of second-line tyrosine kinase inhibitors (TKIs) after first-line immunotherapy-based (IO) treatment in advanced hepatocellular carcinoma (HCC) is not well-established.
METHODS: A systematic search was conducted to identify studies reporting outcomes with second-line TKIs after progression on first-line IO-based treatment. This reconstructed individual patient data (IPD) meta-analysis used survival data reconstructed from published Kaplan-Meier curves. Studies presenting or combining third-…
Rank106.3
Systematic review or meta-analysisResult signal: null
Journal of clinical gastroenterology · 2026 · PMID 42090574
BACKGROUND: Esophageal variceal bleeding (EVB) is a life-threatening complication of liver cirrhosis. Carvedilol, a nonselective β-blocker with α1-blocking properties, and endoscopic variceal ligation (EVL) are both recommended for prophylaxis, but their comparative performance remains uncertain.
METHODS: A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted, searching PubMed, Web of Science, and Embase to July 2025. Trials comparing carvedilol with EVL in adults with cirrhosis …
Rank106.3
Systematic review or meta-analysis
HPB : the official journal of the International Hepato Pancreato Biliary Association · 2026 · PMID 42379898
BACKGROUND: Hepatocellular carcinoma (HCC) is the most common primary liver tumor, with transarterial chemoembolization (TACE) and selective internal radiotherapy (SIRT) as main therapeutic options for patients with intermediate-stage HCC. This review compares TACE and SIRT outcomes in unresectable HCC.
METHODS: A literature search identified studies on HCC patients treated with TACE or SIRT. Quality was assessed using the Cochrane risk-of-bias 2 tool. Primary and secondary outcomes included overall survival (OS), …
Rank106.2
Systematic review or meta-analysis
HPB : the official journal of the International Hepato Pancreato Biliary Association · 2026 · PMID 42185159
BACKGROUND: Large scale hepatectomy for primary or metastatic liver tumors may be limited by insufficient Future Liver Remnant (FLR). Strategies to enhance FLR hypertrophy include associating liver partition and portal vein ligation for staged hepatectomy (ALPPS), portal vein embolization (PVE), and Liver Venous Deprivation (LVD). Their comparative efficacy in the context of open hepatectomy remains unclear.
METHODS: A systematic review and meta-analysis of pairwise comparative studies was conducted (PubMed, Embase…
Rank106.0
Systematic review or meta-analysis
The Cochrane database of systematic reviews · 2026 · PMID 42713852
RATIONALE: Chronic hepatitis B is a global public health concern. It is caused by infection with the hepatitis B virus (HBV). The goal of treating chronic HBV infection is to prevent progression to chronic hepatitis, cirrhosis, hepatic decompensation, liver failure, hepatocellular carcinoma, and death. Individual studies have evaluated various immunomodulatory therapies with inconsistent results. Thymosin-ɑ1 is known to have antiviral effects; however, results of randomised clinical trials on the effects of thymosi…
Landmark Evidence47 records
Rank108.9
Systematic review or meta-analysisResult signal: null
Hepatology international · 2024 · PMID 38965190
BACKGROUND AND AIMS: The risk of hepatocellular carcinoma (HCC) occurrence following antiviral therapy in patients with chronic hepatitis C (CHC) remains unclear. The current study aims to compare: (1) the HCC occurrence rate following sustained virological response (SVR) versus non-response (NR); (2) the HCC occurrence rate following direct-acting antiviral (DAA) therapy versus interferon (IFN)-based therapy, and (3) the HCC occurrence rate in SVR patients with or without cirrhosis.
METHODS: A search was performed…
Rank108.6
Systematic review or meta-analysis
International journal of radiation oncology, biology, physics · 2024 · PMID 37597757
This systematic review and meta-analysis reports on outcomes and hepatic toxicity rates after stereotactic body radiation therapy (SBRT) for liver-confined hepatocellular carcinoma (HCC) and presents consensus guidelines regarding appropriate patient management. Using the Preferred Reporting Items for Systemic Review and Meta-Analyses guidelines, a systematic review was performed from articles reporting outcomes at ≥5 years published before October 2022 from the Embase, MEDLINE, Cochrane, and Scopus databases with …
Rank107.7
Systematic review or meta-analysis
BMC cancer · 2024 · PMID 39160484
BACKGROUND: The selection of appropriate second-line therapy for liver cancer after first-line treatment failure poses a significant clinical challenge due to the lack of direct comparative studies and standard treatment protocols. A network meta-analysis (NMA) provides a robust method to systematically evaluate the clinical outcomes and adverse effects of various second-line treatments for hepatocellular carcinoma (HCC).
METHODS: We systematically searched PubMed, Embase, Web of Science and the Cochrane Library to…
Rank107.6
Systematic review or meta-analysis
Digestive diseases and sciences · 2024 · PMID 38867097
BACKGROUND: Hepatic complications are increasingly recognized after the Fontan operation. The development of hepatocellular carcinoma (HCC) is associated with high mortality when diagnosed, but its incidence and risk factors are poorly understood. We conducted a systematic review and meta-analysis of the cumulative incidence of HCC after Fontan and associated risk factors.
METHODS: We searched PubMed, CINAHL, and MEDLINE databases for articles reporting the cumulative incidence of HCC after Fontan operation on Marc…
Rank107.5
Systematic review or meta-analysis
Current oncology (Toronto, Ont.) · 2024 · PMID 39590162
Background: Hepatocellular carcinoma (HCC) is a prevalent liver cancer with poor prognosis, often linked to hepatitis B (HBV) and C (HCV) infections. This meta-analysis evaluates the efficacy of immunotherapy in HCC, particularly in cases arising from viral hepatitis. Methods: In adherence to PRISMA Statement 2020 guidelines, the immunotherapeutic outcomes comprised objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). Data were analyzed from randomized controlled trials up to A…
Rank107.0
Systematic review or meta-analysis
Metabolism: clinical and experimental · 2021 · PMID 33891949
BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related death worldwide. Effects of second-line oral antidiabetic medications on incident HCC risk in individuals with type 2 diabetes mellitus remain unclear. This study evaluated associations between sulfonylureas, thiazolidinediones, meglitinides and alpha-glucosidase inhibitors, and incident HCC risk.
METHODS: We systematically reviewed all studies on PubMed, Embase and Web of Science databases. Studies were included if they doc…
Rank107.0
Systematic review or meta-analysis
Journal of hepatology · 2022 · PMID 35139400
BACKGROUND & AIMS: There is controversy regarding the overall value of hepatocellular carcinoma (HCC) surveillance in patients with cirrhosis given the lack of data from randomized-controlled trials. To address this issue, we conducted a systematic review and meta-analysis of cohort studies evaluating the benefits and harms of HCC surveillance in patients with cirrhosis.
METHODS: We performed a search of the Medline and EMBASE databases and national meeting abstracts from January 2014 through July 2020 for studies …
Rank107.0
Systematic review or meta-analysis
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023 · PMID 35940513
BACKGROUND & AIMS: Alcohol is one of the leading causes of hepatocellular carcinoma (HCC). However, pooled estimates of HCC incidence in alcohol-associated cirrhosis have not been evaluated systematically. We performed a pooled analysis of time-to-event data to provide robust estimates for the incidence of HCC in alcohol-associated cirrhosis.
METHODS: Medline, Embase, Cochrane Central Register, Scopus, and Web of Science were searched from inception to August 2021. Individual patient data were reconstructed from pu…
Rank107.0
Systematic review or meta-analysis
Digestive diseases and sciences · 2023 · PMID 35767138
BACKGROUND & AIMS: Physical activity offers promise to protect against multiple non-hepatic primary cancers. We performed a systematic review to quantify the association between physical activity and hepatocellular carcinoma (HCC) risk.
METHODS: We searched the Cochrane Library, Embase, Medline and trial registries through December 2020 for studies that measured physical activity levels in adults at risk for HCC. The primary outcome was HCC. Subgroup analysis was performed limiting to vigorous physical activity. Pr…
Rank106.5
Systematic review or meta-analysis
Frontiers in public health · 2022 · PMID 35252078
BACKGROUND: The association between environmental and socioeconomic risk factors and the occurrence of hepatocellular carcinoma (HCC) are still inconclusive. A meta-analysis was conducted to address this issue.
METHODS: We systematically searched the databases including PubMed, Web of Science, and Google Scholar and collected the related risk factors of HCC before March 6, 2020. Statistical analysis was performed on the odds ratio (OR) value and 95% CI of the correlation between environmental and socioeconomic fact…
Rank106.3
Systematic review or meta-analysis
Frontiers in immunology · 2024 · PMID 38887293
BACKGROUND: Multiple investigations and scholarly articles have presented compelling evidence indicating that tertiary lymphoid structures (TLS) play a pivotal role in inhibiting and controlling the advancement of tumors. While there is an abundance of information highlighting the importance of TLS in different cancer types, their prognostic significance specifically in hepatocellular carcinoma (HCC) cancers remains unclear. Thus, this meta-analysis aimed to explore the prognostic relevance of TLS in HCC.
METHODS: …
Rank105.7
Systematic review or meta-analysis
Gastroenterology · 2021 · PMID 34126063
BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with a rapidly changing landscape of treatments. In the past 20 years, numerous randomized controlled trials (RCTs) have aimed at improving outcomes across disease stages. We aimed to analyze the current evidence and identify potential factors influencing response to therapies.
METHODS: We conducted a systematic review of phase III RCTs (2002-2020) across disease stages. A meta-analysis was designed to examine the rela…
Rank105.0
Systematic review or meta-analysis
Journal of gastroenterology and hepatology · 2024 · PMID 38686439
BACKGROUND AND AIM: The purpose of the current study was to investigate the predictive value of hepatitis B core-related antigen (HBcrAg) on the occurrence and recurrence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB).
METHODS: We searched PubMed, Embase, Scopus, and Web of Science from database inception to April 6, 2023. Pooled hazard ratio (HR) or odds ratio (OR) with 95% confidence interval (CI) was calculated for the occurrence and recurrence of HCC.
RESULTS: Of the 464 articles c…
Rank104.8
Systematic review or meta-analysisResult signal: mixed
Frontiers in immunology · 2024 · PMID 38440727
BACKGROUND: Neoadjuvant immunotherapy has demonstrated beneficial outcomes in various cancer types; however, standardized protocols for neoadjuvant immunotherapy in hepatocellular carcinoma (HCC) are currently lacking. This systematic review and meta-analysis aims to investigate the reliability of neoadjuvant immunotherapy's efficacy and safety in the context of HCC.
METHODS: A systematic search was conducted across PubMed (MEDLINE), EMBASE, the Web of Science, the Cochrane Library, and conference proceedings to id…
Rank104.7
Systematic review or meta-analysisResult signal: benefit
Clinical and experimental medicine · 2023 · PMID 35737170
INTRODUCTION: Preclinical data have revealed that beta-adrenergic stimulation can affect the growth and progression of different types of malignancies. Beta-adrenergic receptor blockers have been associated with improved survival in patients with many types of cancer. We performed a meta-analysis to investigate the association between beta-blocker use and hepatocellular carcinoma (HCC) prognosis.
METHODS: In this meta-analysis, a full search was conducted using PubMed, the Cochrane library and Embase to identify al…
Rank103.9
Systematic review or meta-analysis
Journal of hepatology · 2021 · PMID 33548385
BACKGROUND & AIMS: Biannual ultrasound has poor sensitivity for hepatocellular carcinoma (HCC) screening. MRI is accurate for the detection of HCC, but a complete MRI is not feasible as a screening tool. Abbreviated MRI (AMRI) is an acceptable alternative. The diagnostic performance of different AMRI protocols is not known. We performed a systematic review to determine the diagnostic accuracy of AMRI for HCC screening.
METHODS: We searched the MEDLINE and EMBASE databases for studies reporting the diagnostic accura…
Rank103.3
Systematic review or meta-analysis
Gut · 2021 · PMID 32398224
BACKGROUND: Tumour growth patterns have important implications for surveillance intervals, prognostication and treatment decisions but have not been well described for hepatocellular carcinoma (HCC). The aim of our study was to characterise HCC doubling time and identify correlates for indolent and rapid growth patterns.
METHODS: We performed a systematic literature review of Medline and EMBASE databases from inception to December 2019 and national meeting abstracts from 2010 to 2018. We identified studies reportin…
Rank103.0
Systematic review or meta-analysis
BMC medicine · 2024 · PMID 39736748
BACKGROUND: Risk prediction models can identify individuals at high risk of chronic liver disease (CLD), but there is limited evidence on the performance of various models in diverse populations. We aimed to systematically review CLD prediction models, meta-analyze their performance, and externally validate them in 0.5 million Chinese adults in the China Kadoorie Biobank (CKB).
METHODS: Models were identified through a systematic review and categorized by the target population and outcomes (hepatocellular carcinoma…
Rank103.0
Systematic review or meta-analysisResult signal: harm
Scientific reports · 2016 · PMID 27642100
Antidiabetic medication may modify the incidence of hepatocellular carcinoma (HCC). We aimed to compare the use of different antidiabetic strategies and the incidence of HCC. PubMed, Embase.com and Cochrane Library databases were searched up to 31 October 2015 and randomized controlled trials (RCTs), cohort studies or case-control studies were included for our analyses. A total of thirteen studies enrolling 481358 participants with 240678 HCC cases who received at least two different strategies were retrieved in th…
Rank102.9
Systematic review or meta-analysis
United European gastroenterology journal · 2023 · PMID 37736854
BACKGROUND/AIMS: Transjugular intrahepatic portosystemic shunts (TIPS) in patients with hepatocellular carcinoma (HCC) may improve access to curative therapies, treat portal hypertension (PH)-related complications without worsening liver function, and increase overall survival. Data on the efficacy and safety of TIPS to treat PH complications in HCC patients, as well as the HCC treatment response, were evaluated.
METHODS: Studies reporting efficacy in controlling bleeding/ascites or response to HCC therapy, safety,…
Rank102.9
Systematic review or meta-analysis
Expert review of gastroenterology & hepatology · 2018 · PMID 30004289
BACKGROUND: ABO blood type is an invariant factor. There is a link between ABO blood type and some malignancies, such as gastric, pancreatic, and skin cancer. The role of ABO blood type in the pathogenesis of hepatocellular carcinoma (HCC) remains controversial. We performed a meta-analysis to explore the relationship between ABO blood type and risk of HCC.
METHODS: Literature search was conducted among the PubMed, EMBASE, and Cochrane Library databases. Odds ratios (ORs) and 95% confidence intervals (CIs) were cal…
Rank102.9
Systematic review or meta-analysisResult signal: benefit
Oncotarget · 2016 · PMID 26943041
OBJECTIVES: Usage of statins is suggested to decrease the incidence of HCC. When it comes to different statin subtypes, the chemopreventive action remains controversial. We aim to compare the usage of different statins and reduction of HCC risk.
METHODS: We searched PubMed, Embase.com and Cochrane Library database up to August 10, 2015. Duplicated or overlapping reports were eliminated. We performed a traditional pair-wise meta-analysis and a Bayesian network meta-analysis to compare different treatments with a ran…
Rank102.9
Systematic review or meta-analysis
Academic radiology · 2024 · PMID 38413315
BACKGROUND: Given the limited sensitivity of ultrasound in hepatocellular carcinoma (HCC) surveillance, this systematic review and meta-analysis were aimed to assess the diagnostic performance of non-contrast abbreviated MRI (NC-aMRI) compared to contrast-enhanced abbreviated MRI (CE-aMRI) for HCC surveillance, offering evidence-based guidance for clinical decision-making.
METHODS: A comprehensive search was conducted across five databases, identifying studies on aMRI for HCC surveillance. The pooled sensitivity an…
Rank102.8
Systematic review or meta-analysis
PloS one · 2022 · PMID 36584078
BACKGROUND: To evaluate the clinical value of Aldo-keto reductase family 1 member B10 (AKR1B10) in the diagnosis and prognosis of hepatocellular carcinoma (HCC).
METHODS: A search of the PubMed, China Biology Medicine, Cochrane, and Embase databases was performed to conduct meta-analyses to evaluate the accuracy of AKR1B10 in diagnosing HCC and to assess the impact on prognosis of patients after curative resection of HCC.
RESULTS: A total of 12 different cohorts from 11 studies including 2747 HCC patients and 2053 …
Rank102.0
Systematic review or meta-analysis
Clinical and molecular hepatology · 2024 · PMID 38623613
BACKGROUND/AIMS: The global proportion of hepatocellular carcinoma (HCC) attributable to metabolic dysfunction-associated fatty liver disease (MAFLD) is unclear. The MAFLD diagnostic criteria allows objective diagnosis in the presence of steatosis plus defined markers of metabolic dysfunction, irrespective of concurrent liver disease. We aimed to determine the total global prevalence of MAFLD in HCC cohorts (total-MAFLD), including the proportion with MAFLD as their sole liver disease (single-MAFLD), and the propor…
Most Effective Evidence Supported Treatments214 records
Rank112.2
Systematic review or meta-analysis
Cancer medicine · 2026 · PMID 42047297
OBJECTIVE: Microvascular invasion (MVI) has been identified as a risk factor for the prognosis of patients with hepatocellular carcinoma (HCC). However, it can only be diagnosed pathologically, and thus no widely applicable preoperative MVI risk prediction model has been established. The aim of this study was to develop a preoperative predictive model for MVI.
DESIGN: The model derivation set was derived from a global meta-analysis involving 39,253 patients. Model validation was performed at the First Affiliated Ho…
Rank112.0
Clinical guideline or consensus statement
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2026 · PMID 41490582
The success of living donor liver transplantation (LDLT) has bridged the growing gap between organ demand and availability in patients with liver failure or liver cancer. Safety of the living liver donor (LLD) is paramount, and astute intraoperative management plays a critical role in ensuring optimal outcomes for them. Given that intraoperative surgical and anesthesia practices vary widely across centers, the International Liver Transplantation Society (ILTS) and the International Living Donor Liver Transplantatio…
Rank110.0
Systematic review or meta-analysis
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2026 · PMID 42285810
BACKGROUND AND AIMS: Statins have been proposed as hepatoprotective agents in chronic liver disease (CLD); however, evidence from existing systematic reviews-including observational studies and clinical trials-is inconsistent and affected by substantial overlap. We conducted an umbrella review to synthesize the available evidence on the associations between statin use and hepatological outcomes in CLD patients, while addressing study overlap.
DESIGN: PubMed, EMBASE, and Cochrane Library were searched up to Septembe…
Rank110.0
Clinical guideline or consensus statement
Journal of hepatology · 2026 · PMID 42191458
Steatotic liver disease (SLD) comprises a heterogeneous group of liver diseases defined by pathological hepatic lipid accumulation with varying degrees of steatohepatitis and progressive fibrosis, which may culminate in cirrhosis and/or hepatocellular carcinoma. SLD encompasses metabolic dysfunction-associated steatotic liver disease (MASLD), formerly called non-alcoholic fatty liver disease (NAFLD); MetALD, describing patients with MASLD consuming moderately high amounts of alcohol; and alcohol-associated/related …
Rank110.0
Clinical guideline or consensus statement
Hepatology (Baltimore, Md.) · 2026 · PMID 41405234
BACKGROUND AND AIMS: Liver transplant is a specialized treatment for a spectrum of indications that use a scarce resource. Transplant is guided by principles of justice, equity, and benefit, with a constant conflict between competing interests. Organs are a national resource with a goal of equitable distribution across sites. An AASLD guideline for the evaluation and selection of appropriate candidates for transplant has been available since 2005.
METHODS: A multidisciplinary writing group of liver transplant exper…
Rank110.0
Clinical guideline or consensus statement
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025 · PMID 41167769
Chronic hepatitis B functional (clinical) cure is currently an important therapeutic endpoint, which significantly reduces the incidence risk of cirrhosis and liver cancer. This expert consensus focuses on key clinical issues on the basis of previous studies, systematically elaborates population stratification and stepwise treatment strategies based on patient characteristics, consolidation therapy, relapse management, long-term monitoring after serum HBsAg clearance, and optimal management for patients who have no…
Rank110.0
Clinical guideline or consensus statement
Gastroenterology · 2026 · PMID 42017860
DESCRIPTION: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death in patients with cirrhosis. Although advancements in surgical, locoregional, and systemic therapies have improved outcomes for patients with early-stage HCC, most cases are diagnosed at later stages due to both the limitations of currently recommended surveillance modalities and their underuse, with fewer than 1 in 4 patients with cirrhosis receiving surveillance for this tumor. Current guidelines recommend semiannual surveillanc…
Rank110.0
Clinical guideline or consensus statement
Journal of gastroenterology · 2026 · PMID 42120590
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, with an increasing number of patients progressing to cirrhosis and hepatocellular carcinoma (HCC). Early identification of individuals at high risk for advanced fibrosis is essential for preventing liver-related events and improving long-term outcomes. This guideline summarizes current evidence and provides practical recommendations for the diagnosis, risk stratification, and managemen…
Rank109.8
Systematic review or meta-analysis
Alimentary pharmacology & therapeutics · 2026 · PMID 41518144
BACKGROUND: The role of statins in cirrhosis remains controversial. Historically restricted due to safety concerns, emerging evidence highlights potential pleiotropic benefits, though effects on mortality and decompensation remain uncertain.
AIMS: To evaluate the effects of statin therapy on all-cause mortality, hepatic decompensation, hepatic venous pressure gradient (HVPG), and hepatocellular carcinoma (HCC) in cirrhosis.
METHODS: We systematically searched major databases until July 2025 for randomised controlle…
Rank109.7
Systematic review or meta-analysis
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2026 · PMID 42314305
BACKGROUND: Multidisciplinary team (MDT) management is widely endorsed for complex hepatobiliary and pancreatic (HBP) malignancies. However, robust systematic evidence evaluating its survival benefits and heterogeneity across distinct anatomical sites remains limited.
METHODS: Our study systematically searched four databases from their inception through Dec 17, 2025, for studies comparing MDT versus non-MDT care in HBP malignancies. The primary outcome was overall survival or mortality risk. Secondary outcomes incl…
Rank109.6
Systematic review or meta-analysis
Liver international : official journal of the International Association for the Study of the Liver · 2026 · PMID 41797383
Cholangiocarcinoma (CCA) is the second most common primary liver cancer and is being diagnosed with increasing frequency worldwide. We performed a systematic review on radiofrequency (RFA), microwave (MWA), irreversible electroporation (IRE), trans-arterial chemoembolization (TACE) and selective internal radiation therapy (SIRT) in CCA. Thirty-one ablation studies (1526 patients), 21 TACE studies (1594 patients), and 38 SIRT studies (1954 patients) were included; most cohorts involved intrahepatic CCA (iCCA) and or…
Rank109.5
Systematic review or meta-analysisResult signal: benefit
BMC cancer · 2026 · PMID 41566457
BACKGROUND: Increasing studies have examined the combination of traditional Chinese medicine (TCM) with Transcatheter arterial chemoembolization (TACE) in treating liver cancer. However, these results were inconsistent in immune function. Therefore, our study aimed to conduct a meta-analysis to evaluate the immune function of TCM combined with TACE in liver cancer patients.
METHODS: Seven electronic databases were retrieved from January 1, 2014, to January 6, 2025. The Cochrane Risk of Bias 2.0 tool was used to ass…
Rank109.4
Systematic review or meta-analysis
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 42139645
PURPOSE: External beam radiation therapy (EBRT) has gained delayed acceptance as a recommended first-line treatment modality for patients with hepatocellular carcinoma (HCC), given limited evidence that it improves overall survival (OS). We analyzed individual patient data (IPD) from an international cohort to assess OS among patients with HCC treated with EBRT.
METHODS: We performed a systematic review of publications that assessed EBRT, met prespecified technical standards for HCC, and reported OS (search date De…
Rank108.9
Systematic review or meta-analysis
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2026 · PMID 41999909
BACKGROUND: The management of multiple bilobar colorectal liver metastases (BCRLMs) continues to evolve, and the optimal strategy remains controversial. This was a systematic review that analyzed the outcomes of different surgical strategies for BCRLMs.
METHODS: A systematic literature search that included MEDLINE, Embase, and the Cochrane Library was performed according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines and registered in the International Prospective Register of S…
Rank108.8
Systematic review or meta-analysisResult signal: benefit
Critical reviews in oncology/hematology · 2026 · PMID 41905568
BACKGROUND: Liver metastases have been associated with poor prognosis and potentially diminished immunotherapy benefit. Comprehensive evidence regarding whether liver involvement affects the efficacy of immune checkpoint inhibitor plus chemotherapy regimens remains incomplete.
METHODS: Following PRISMA guidelines, we systematically searched five databases through May 2025 for randomized controlled trials comparing chemoimmunotherapy versus chemotherapy alone in solid tumors, with survival data stratified by liver m…
Rank108.6
Systematic review or meta-analysis
Hepatology communications · 2026 · PMID 42043878
BACKGROUND: The clinical impact of hepatic steatosis (HS) among patients with autoimmune liver disease (AILD) remains unclear. We aim to determine the prevalence of HS and its clinical impact on treatment response and outcomes in patients with AILD.
METHODS: We systematically searched 3 electronic databases until 17 December 2025, including all studies that reported the prevalence, clinical impact, and treatment response of AILD patients with concomitant HS. The temporal trend of HS prevalence was analyzed using a …
Rank108.4
Systematic review or meta-analysis
European journal of gastroenterology & hepatology · 2026 · PMID 41604560
Hepatic failure is a potentially fatal complication in hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE). However, there is a lack of clear predictive factors for hepatic failure after TACE in HCC patients. This study aimed to identify all available data and determine the risk factors associated with hepatic failure after TACE in HCC patients. A systematic review and meta-analysis included 9 studies with a total of 1654 patients. The results showed that factors significantly …
Rank108.2
Systematic review or meta-analysis
Frontiers in immunology · 2026 · PMID 41705252
OBJECTIVE: To assess platelet-to-lymphocyte ratio (PLR) prognostic utility for overall (OS) and progression-free survival (PFS) in immune checkpoint inhibitor-treated cancer patients, and examine impacts of geography, cancer type, cutoff, ICI class, treatment line and stage.
METHODS: A systematic literature search identified studies investigating PLR and prognosis in ICI treated patients. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using random-effects models. Subgroup analyses examined key …
Rank108.0
Systematic review or meta-analysis
Journal of robotic surgery · 2026 · PMID 41910840
Robotic hepatectomy has recently been developed as an alternative to laparoscopic and open approaches for hepatocellular carcinoma (HCC) treatment. However, comparative studies are lacking. We conducted a PRISMA-NMA–compliant systematic review (PROSPERO CRD420251265604) of databases, comparing robot-assisted hepatectomy with laparoscopic/open resection for adult HCC. We used ROBINS-I to assess bias and GRADE to assess evidence. Frequentist random-effects NMA estimated OR/MD, with consistency, ranking, and CINeMA ce…
Rank107.9
Systematic review or meta-analysisResult signal: null
Journal of neurology · 2026 · PMID 42251157
BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment with significant improvements in survival rates. With the increase in ICI use in the clinical setting, several case reports and series have described neurological adverse events associated with it. We conducted this systematic review and meta-analysis to estimate the incidence of neurological adverse events among ICI clinical trials.
METHODS: We searched PubMed, Embase, Scopus, and the Cochrane Central Register of Controlled Trials…
Rank107.9
Systematic review or meta-analysis
Gut and liver · 2026 · PMID 42379830
BACKGROUND/AIMS: The role of direct-acting antivirals (DAAs) in patients with hepatocellular carcinoma (HCC) remains uncertain due to conflicting data on virologic efficacy and long-term outcomes.
METHODS: This meta-analysis investigated studies reporting the sustained virologic response (SVR), recurrence, and overall survival in patients with HCC treated with DAAs.
RESULTS: Eighty-eight studies were included, comprising 8,839 patients with HCC who were treated with DAAs. The pooled SVR rate in patients with HCC wa…
Rank107.9
Systematic review or meta-analysis
BJS open · 2025 · PMID 40164991
BACKGROUND: Robotic techniques can theoretically overcome the limitations of laparoscopic liver resection and are currently recognized as safe options; however, it is not known which approach is better. The purpose of this study was to compare the advantages of robotic hepatectomy and laparoscopic hepatectomy.
METHODS: Electronic databases (the Cochrane Library, PubMed (MEDLINE), Embase and Web of Science) were systematically searched from January 2000 to August 2023 for eligible studies that compared robotic hepat…
Rank107.7
Systematic review or meta-analysisResult signal: benefit
Frontiers in immunology · 2026 · PMID 42220514
BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized the front-line treatment of advanced hepatocellular carcinoma (HCC). However, the comparative efficacy and safety of different ICI-based regimens-and their consistency across etiologic subgroups [HBV, HCV, and non-HBV/non-HCV (NBNC)]-remain uncertain. This study conducted a Bayesian network meta-analysis (NMA) of recent randomized controlled trials (RCTs) to compare the first-line immunotherapy strategies both overall and by viral etiology.
METHODS…
Rank107.7
Systematic review or meta-analysis
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2026 · PMID 41996777
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, and accurate staging is crucial to avoid unnecessary surgery. MRI may improve the detection of occult liver metastases when compared with CT. The impact of adding MRI on treatment timelines and cost-effectiveness remains uncertain. This systematic review synthesises the available evidence of incorporating MRI alongside CT for pre-operative staging of pancreatic cancer.
METHODS: We systematically searched MEDLINE, Embase, Web of Science, and t…
Rank107.6
Systematic review or meta-analysis
JAMA network open · 2026 · PMID 42084869
IMPORTANCE: Circadian rhythms affect immunity, which could affect the effectiveness of immune checkpoint inhibitor (ICI). Whether the time of ICI administration is associated with clinical outcomes in advanced cancers remains unclear.
OBJECTIVE: To evaluate the association between time of day of ICI administration and oncologic outcomes in patients with advanced solid tumors.
DATA SOURCES: MEDLINE (via PubMed), Embase, and Web of Science Core Collection were searched in February 2026 to identify eligible studies.
S…
New Research Last 24 Months282 records
Rank105.3
Systematic review or meta-analysis
European journal of cancer (Oxford, England : 1990) · 2026 · PMID 42330566
BACKGROUND: Evidence on the efficacy of percutaneous hepatic perfusion (PHP) in metastatic uveal melanoma (mUM) is largely derived from single-arm studies without comparators, complicating interpretation of treatment benefit, particularly for survival. This meta-analysis aimed to synthesize available evidence on the efficacy and safety of PHP in patients with mUM and compare outcomes with best alternative care (BAC).
MATERIAL AND METHODS: PubMed, Embase, Cochrane, and Web of Science were searched from database ince…
Rank104.2
Systematic review or meta-analysis
AJR. American journal of roentgenology · 2026 · PMID 42018773
BACKGROUND. In LI-RADS CT/MRI version 2018 (v2018), ancillary features (AFs) support observation characterization and category assignment. The literature is lacking regarding interreader agreement on a broad range of AFs. OBJECTIVE. The purpose of the present study was to conduct a systematic review and meta-analysis of the interreader agreement for all individual AFs in LI-RADS CT/MRI v2018 and to identify factors associated with interpretation variability. EVIDENCE ACQUISITION. The MEDLINE, Embase, and Cochrane d…
Rank102.8
Systematic review or meta-analysis
ESMO gastrointestinal oncology · 2026 · PMID 42582959
BACKGROUND: Transarterial chemoembolization (TACE) is the standard of care for intermediate-stage unresectable hepatocellular carcinoma (HCC), but progression-free survival (PFS) with TACE alone remains limited. Recent randomized clinical trials have evaluated the addition of immune checkpoint inhibitors (ICIs) to TACE. We conducted a meta-analysis of randomized trials to assess the efficacy and safety of TACE plus ICIs versus TACE alone in unresectable HCC.
MATERIALS AND METHODS: A systematic search of PubMed, Emb…
Rank100.0
Systematic review or meta-analysis
Clinica chimica acta; international journal of clinical chemistry · 2026 · PMID 42248317
BACKGROUND: Exosomal microRNAs (miRNAs) have emerged as promising non-invasive biomarkers for hepatocellular carcinoma (HCC). Nevertheless, the overall diagnostic performance of exosomal miRNAs in HCC was still less reported. Therefore, this meta-analysis aimed to systematically assess the pooled diagnostic efficacy of exosomal miRNAs for HCC.
METHODS: A literature search was performed in accordance with the PRISMA guidelines, utilizing the PubMed, Web of Science, EMBASE, and CNKI databases up to December 22, 2024.…
Rank100.0
Systematic review or meta-analysis
Annals of surgical oncology · 2026 · PMID 42303818
BACKGROUND: After curative-intent pancreatectomy for pancreatic ductal adenocarcinoma (PDAC), disease recurrence occurs almost invariably. Evidence guiding treatment of recurrence remains limited and may differ across single-site recurrence patterns.
METHODS: Scopus, MEDLINE, and the Cochrane Library were systematically searched for observational studies of adults with recurrent PDAC reporting liver-only, lung-only, or locoregional recurrence and post-recurrence treatments. Hazard ratio (HR) meta-analyses were perf…
Rank96.0
Systematic review or meta-analysis
Clinical and translational radiation oncology · 2026 · PMID 42471954
Stereotactic body radiotherapy (SBRT) is an established locoregional treatment option for hepatocellular carcinoma (HCC). However, post-treatment imaging remains challenging because tumor response and focal liver reaction (FLR), defined as radiation-related alterations of the adjacent liver parenchyma, may both evolve gradually and mimic viable or recurrent tumor. We conducted a scoping review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PR…
Rank92.0
Randomized controlled trial
BMJ open · 2026 · PMID 42586727
INTRODUCTION: Recognising and acting on the connection to Country as a determinant of Indigenous peoples' well-being is necessary to improve health inequities. Indigenous Australians experience a greater burden of chronic liver disease and poorer outcomes due to ongoing impacts of colonisation across determinants of health. This is exacerbated by a gradient in health outcomes based on remoteness, lack of specialist healthcare services and barriers to access. Our research aims to explore better ways to provide chron…
Rank89.1
Randomized clinical studyResult signal: benefit
Journal of integrative and complementary medicine · 2026 · PMID 42578431
BACKGROUND: This study was designed to assess the safety and preliminary efficacy of Sanshimao (SSM) formula in early and intermediate hepatocellular carcinoma (HCC) patients with cirrhosis.
METHODS: We conducted a prospective randomized, open-label, controlled trial, assigning early and intermediate HCC patients with cirrhosis in a 1:1 ratio to either the control group or the SSM group. Patients were followed for a 16-month treatment period. Patients in the SSM group received additional SSM formula in addition to …
Rank85.0
Randomized clinical study
Nuclear medicine communications · 2026 · PMID 42169550
BACKGROUND: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) demonstrating liver-dominant inoperable metastatic diseases or locally advanced inoperable tumors may at times show reduced efficacy for intravenous peptide receptor radionuclide therapy (PRRT).
AIMS AND OBJECTIVES: To determine and compare the outcome of intra-arterial [ 177 Lu]Lu-DOTATATE PRRT in GEP-NET with locally advanced inoperable primary or liver-dominant metastases who had shown no response after at least two cycles of intravenous [ 177 L…
Rank81.5
Multicenter clinical studyResult signal: harm
American journal of ophthalmology · 2026 · PMID 42229563
PURPOSE: Understanding how the risk of immune checkpoint inhibitor (ICI)-associated noninfectious uveitis (NIU) differs by malignancy and drug class may help understand its pathophysiology and guide targeted ophthalmic surveillance. This study aims to evaluate the comparative risk of ICI-associated NIU across different malignancies and drug classes.
DESIGN: Retrospective, multicenter clinical cohort study.
SUBJECTS: Adults with metastatic melanoma, lung cancer, renal cell carcinoma (RCC), urothelial carcinoma, hepa…
Rank80.5
Multicenter clinical study
European journal of radiology · 2026 · PMID 42229038
OBJECTIVES: To investigate the association between baseline body composition and objective response to first-line bevacizumab-based chemotherapy in patients with unresectable colorectal liver metastases (CRLM), and to develop a model for response prediction in this treatment setting.
METHODS: This multicenter retrospective cohort included 185 patients with newly diagnosed unresectable CRLM from three hospitals who received first-line bevacizumab therapy. Pre-treatment body composition parameters were quantified at …
Rank79.8
Multicenter clinical study
European radiology · 2026 · PMID 42053592
OBJECTIVES: Transarterial chemoembolization (TACE) is a promising locoregional therapy for unresectable colorectal liver metastases, but patient selection remains challenging. We aimed to develop and validate prognostic radiomics-based machine learning models in a multicenter, prospectively collected drug-eluting microsphere TACE cohort.
MATERIALS AND METHODS: We retrospectively analyzed 76 patients (176 lesions) from the prospective CIREL registry trial. Radiomic features were extracted from each lesion. We tested…
Rank78.3
Multicenter clinical studyResult signal: benefit
Annals of surgical oncology · 2026 · PMID 42223775
BACKGROUND: The AFP model, originally developed to refine biological selection for liver transplantation, integrates tumor size, number, and serum AFP level. It was shown to be superior to the Milan criteria for predicting hepatocellular carcinoma (HCC) after liver transplantation. Although widely validated in the transplant setting, its prognostic value after hepatic resection for HCC remains insufficiently defined. This study aimed to assess the performance of the AFP score in predicting recurrence and survival a…
Rank78.2
Multicenter clinical study
European journal of radiology · 2026 · PMID 42320144
OBJECTIVES: To investigate the diagnostic performance of the quantitative morphological feature of solidity in preoperative prediction of proliferative hepatocellular carcinoma (HCC), and to compare the diagnostic performance between quantitative morphological features and machine learning (ML) models that incorporate Sonazoid contrast-enhanced ultrasound (CEUS) and clinical features.
METHODS: This retrospective two-center study included 395 patients with histopathologically confirmed HCC. The morphological feature…
Rank78.0
Multicenter clinical study
Signal transduction and targeted therapy · 2026 · PMID 42581040
Transarterial chemoembolization (TACE) remains a cornerstone therapy for intermediate-to-advanced hepatocellular carcinoma (HCC); however, the optimal embolic platform remains uncertain. This multicenter, retrospective, real-world study (Clinical trial registration number: ChiCTR2500113198) conducted across China compared a novel temperature-sensitive liquid embolic agent, TempSLE-TACE (T-TACE), with conventional drug-eluting bead TACE (D-TACE) in 328 patients with Barcelona Clinic Liver Cancer (BCLC) stage B/C HCC…
Rank76.0
Multicenter clinical study
European journal of radiology · 2026 · PMID 42413246
OBJECTIVES: Hepatocellular carcinoma (HCC) remains a major cause of cancer-related mortality, with early progression (PD) after treatment posing a critical challenge. Reliable predictive models applicable to different treatment modalities are essential for risk stratification and individualized therapy.
MATERIALS AND METHODS: In this multicenter retrospective study, 249 HCC patients from five institutions underwent curative resection or TACE with pre-treatment multiphase MRI. Radiomic features were extracted from i…
Rank73.0
Multicenter clinical study
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2026 · PMID 42338223
PURPOSE: To fully exploit the advantages of ablation planning software, discrepancies between predicted and actual ablation zones should be minimized. This study evaluated the volumetric and geometric correspondence between manufacturer-predicted and actual ablation zones following thermal liver ablation.
METHODS: This multicenter retrospective study included Emprint microwave ablations with intraprocedural needle and post-ablation confirmation CT scans. The needle position was determined on the needle confirmation…
Rank57.2
Other PubMed-indexed publication
Asia-Pacific journal of oncology nursing · 2026 · PMID 41858761
OBJECTIVE: To develop a clinical model for the early prediction of moderate-to-severe pain after Hepatic Artery Infusion Chemotherapy (HAIC) in liver cancer patients using XGBoost algorithm and then compare its prediction capacity with the logistic model.
METHODS: A multicenter cohort study presented according to TRIPOD + AI statement, which was conducted in 3 tertiary hospitals in Shanghai from May 2022 to June 2024. Lasso regression was used to screen for risk factors. Logistic regression and XGBoost algorithm we…
Rank56.2
Other PubMed-indexed publication
The Prostate · 2026 · PMID 42263174
BACKGROUND: Metastatic prostate cancer (mPCa) exhibits highly complex metastatic patterns. Comprehensive evaluation of distinct metastatic patterns and their integrated prognostic impact remains lacking.
METHODS: Patients with mPCa were identified from the Surveillance, Epidemiology, and End Results (SEER) database, and metastatic patterns were systematically characterized. Cancer-specific survival (CSS) and overall survival (OS) were estimated using the Kaplan-Meier method and compared using multivariable Cox regr…
Rank55.7
Other PubMed-indexed publication
Abdominal radiology (New York) · 2026 · PMID 42579007
PURPOSE: This study aimed to develop and validate a simplified risk score based on pretreatment Gd‑EOB‑DTPA MRI features for the noninvasive prediction of initial objective response rate (ORR) in patients with unresectable hepatocellular carcinoma (uHCC) undergoing triple therapy (hepatic arterial infusion chemotherapy [HAIC], tyrosine kinase inhibitors, and immune checkpoint inhibitors).
METHODS: This retrospective study enrolled 223 uHCC patients from two medical centers who underwent Gd‑EOB‑DTPA‑enhanced MRI pri…
Rank54.5
Other PubMed-indexed publication
Journal of Korean medical science · 2026 · PMID 42576718
BACKGROUND: In August 2017, Republic of Korea (South Korea) expanded its national hospice and palliative care program to cover several serious non-cancer illnesses, including liver cirrhosis (LC). We aimed to examine the access of palliative care services among adults who died of LC compared with those who died of hepatocellular carcinoma (HCC).
METHODS: We conducted a population-based retrospective cohort study using National Health Insurance Service data, including adults who died of LC or HCC between 2018 and 20…
Rank54.4
Other PubMed-indexed publication
Archives of orthopaedic and trauma surgery · 2026 · PMID 42587057
BACKGROUND: Synchronous bone metastases (BM) have a notable impact on the survival rates of patients across various cancer types. While primary tumor surgery (PTS) has shown potential benefits, its impact across different cancers and patient subgroups needs further clarification. This study aimed to investigate the survival benefits of PTS across various cancer types.
METHODS: This retrospective cohort study analyzed data from the Surveillance, Epidemiology, and End Results (SEER) database, covering 53,015 patients…
Rank54.0
Other PubMed-indexed publication
Academic radiology · 2026 · PMID 42586894
RATIONALE AND OBJECTIVES: Microvascular invasion (MVI) is a major driver of recurrence and poor outcomes in hepatocellular carcinoma (HCC), yet biopsy-based pathologic assessment is invasive and susceptible to sampling bias and delayed availability. We aimed to develop and validate a noninvasive preoperative model integrating multiphase magnetic resonance imaging-derived habitat/intratumoral heterogeneity (ITH) features and clinical variables for MVI prediction and postoperative recurrence-risk stratification.
METH…
Rank53.7
Other PubMed-indexed publication
JHEP reports : innovation in hepatology · 2026 · PMID 42580588
BACKGROUND & AIMS: Atezolizumab plus bevacizumab (Atezo/Bev) is considered standard first-line therapy for unresectable hepatocellular carcinoma (HCC), yet reasons for treatment discontinuation vary, and conventional survival endpoints do not capture the time-varying probability of each cause. This multicentre retrospective study aimed to quantify the cause-specific discontinuation and its predictors.
METHODS: We analysed 685 consecutive patients treated with Atezo/Bev (10 excluded). Time to discontinuation was def…
Rank53.6
Other PubMed-indexed publication
International journal of cardiology. Congenital heart disease · 2026 · PMID 42293360
The Fontan procedure is a palliative operation for patients with univentricular physiology. Liver complications post-surgery are inevitable and include liver cirrhosis and hepatocellular carcinoma (HCC). Routine surveillance includes transient elastography (TE) and clinical assessment, however longitudinal data on Fontan-associated liver disease (FALD) is scarce. This study aimed to describe the evolution of FALD and assess the correlation between liver stiffness measurement (LSM) and hepatic decompensation. This r…
Preclinical Research60 records
Rank45.0
Other PubMed-indexed publication
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2026 · PMID 42345510
BACKGROUND AND OBJECTIVE: Microwave ablation is a well-established therapy for liver tumors, but its efficacy is strongly influenced by blood perfusion. Most computational studies simplify perfusion as an isotropic sink, neglecting flow orientation. This work introduces the Antenna-Blood flow Relative Angle (ABRA) to quantify the effects of flow direction and velocity on ablation zone geometry using a commercial ECO Ceramic 14 G antenna.
METHODS: Ex vivo bovine liver experiments were performed under standardized co…
Rank45.0
Other PubMed-indexed publication
Cancer letters · 2026 · PMID 42276407
In colorectal cancer (CRC), tumor-infiltrating regulatory T (Treg) cells suppress anti-tumor immunity, promoting immune evasion and tumor progression. Effective therapies require selectively targeting tumor-infiltrating Treg (TI-Treg) cells while preserving systemic Treg cells, necessitating insight into their adaptations within the tumor microenvironment. Here, CRC-organoids were implanted in the liver of Foxp3eGFP mice to investigate location-specific phenotypic differences in TI-Treg cells. In our cohort, tumor …
Rank43.0
Other PubMed-indexed publicationCorrection flagged
Journal of ethnopharmacology · 2026 · PMID 42142550
ETHNOPHARMACOLOGICAL RELEVANCE: Trametes robiniophila Murr (Huaier) is a traditional Chinese medicine (TCM) with potent immunomodulatory effects. Clinically validated for anti-hepatocellular carcinoma activity, Huaier granules are the mainstream proprietary preparation derived from this fungus. In recent years, polysaccharide components from natural medicinal herbs have attracted extensive research attention owing to their prominent biological activities. Although Huaier has been applied in clinical practice for de…
Rank38.2
Preclinical or laboratory study
Translational oncology · 2026 · PMID 42401103
BACKGROUND: Hepatocellular carcinoma (LIHC) features a complex tumor microenvironment (TME) where tumor-associated neutrophils (TANs) show significant plasticity. The role of aggrephagy-selective autophagy of protein aggregates-in shaping neutrophil heterogeneity and LIHC progression remains poorly understood.
METHODS: We integrated scRNA-seq (183,671 cells), spatial transcriptomics, and bulk datasets (TCGA, GSE39791). Neutrophils (n=12,547) were re-clustered into six subsets, and aggrephagy activity was quantified…
Rank30.0
Preclinical or laboratory study
Cancer letters · 2026 · PMID 42069175
Cancer stemness drives malignant progression and drug resistance in hepatocellular carcinoma (HCC). Although mitochondrial dynamics are known to influence HCC development, the precise mechanisms linking mitochondrial function to stemness remain largely elusive. Integrating bulk and single-cell transcriptomics, we identified Butyrophilin Subfamily 3 Member A3 (BTN3A3) as a novel oncogene driving HCC stemness. BTN3A3 depletion markedly reduced sphere formation, stemness-related gene expression, and the percentage of …
Rank30.0
Preclinical or laboratory study
Cellular signalling · 2026 · PMID 42119668
Immunotherapies have been widely applied to the treatment of hepatocellular carcinoma (HCC), but to date only a minority of patients exhibit dramatic responses. Tumor-associated macrophages (TAMs) are vital components in the tumor microenvironment and are involved in HCC progression. Herein, we confirm the upregulation of PCBP1 expression in TAMs correlates with poor prognosis in HCC patients. The loss of PCBP1 in TAMs promotes M1 like macrophages polarization and suppresses the migration capability of HCC cells in…
Rank30.0
Preclinical or laboratory study
Journal of inorganic biochemistry · 2026 · PMID 42143555
Triple negative breast cancer (TNBC) remains a clinically challenging subtype because it lacks established molecular targets and often depends on cytotoxic chemotherapy. Although doxorubicin (DOX) and mTOR inhibitors such as Torin1 (TOR) exhibit antitumor activity, their clinical use may be constrained by toxicity and resistance. Copper (I) Nicotinate Complex (CNC) has emerged as promising candidates due to their superoxide dismutase (SOD) -mimicking and cytoprotective properties. This study aimed to evaluate the p…
Rank30.0
Preclinical or laboratory studyResult signal: benefit
Cancer letters · 2026 · PMID 42155697
Although immunotherapy-based regimens have improved overall survival for some patients with advanced hepatocellular carcinoma (HCC), many patients ultimately experience disease progression. Macrophages are abundant in the HCC microenvironment and represent promising therapeutic effectors, yet the potential of combining chimeric antigen receptor macrophages (CAR-M) with macrophage checkpoint targeting remains underexplored. Given that glypican-3 (GPC3), a cell-surface heparan sulfate proteoglycan, is highly expresse…
Rank30.0
Preclinical or laboratory study
Cellular signalling · 2026 · PMID 42177959
Hepatocellular carcinoma (HCC) is the most common primary liver cancer, marked by dysregulated cellular processes and limited treatment options, highlighting the need for preventive therapeutic strategies. N-acetylcysteine (NAC), widely used to treat acetaminophen overdose and as a mucolytic agent, has not been mechanistically characterized in HCC. Here, we evaluated the effects of NAC in experimental HCC models, including its role in modulating the Nrf2/Keap1 signaling pathway. HCC was induced in male Fischer-344 …
Rank30.0
Preclinical or laboratory study
Toxicology · 2026 · PMID 42208886
Per- and polyfluoroalkyl substances (PFASs) are widely used in numerous industrial processes and consumer products and are now ubiquitously distributed in the environment, thereby creating multiple routes of human exposure. Their physicochemical properties confer high persistence, bioaccumulation potential, and toxicity, which have raised increasing concern about their long-term impacts on human health. Because of its central role in xenobiotic uptake, metabolism, transport, and excretion, the liver is considered a…
Rank30.0
Preclinical or laboratory study
International immunopharmacology · 2026 · PMID 42250289
CAR T cell therapy has demonstrated remarkable antitumor efficacy in hematologic malignancies, but its application in solid tumors remains challenging. This is primarily due to the suppressive tumor microenvironment, which impedes T cell infiltration and reduces their functionality. Compared with standard intravenous administration, localized delivery strategies offer significant promise for CAR T therapy in solid tumors. Nevertheless, most reported approaches rely on complex biomaterials and are mainly applied in …
Rank30.0
Preclinical or laboratory study
Genes & diseases · 2026 · PMID 42290658
ADAR1 is overexpressed in hepatocellular carcinoma (HCC) and has been linked to poor prognosis, metastasis, and recurrence; however, its precise functions and underlying mechanisms, particularly in the context of metastasis, remain inadequately elucidated. This study seeks to elucidate the functions and underlying mechanisms of the most abundantly expressed isoform of ADAR1, ADAR1p110, in the setting of HCC metastasis. In this study, hepatocyte-specific ADAR1p110 knock-in mice and engineered HCC cell lines were uti…
Rank30.0
Preclinical or laboratory study
Biochemical pharmacology · 2026 · PMID 42297217
Solute carrier family 6 member 8 (SLC6A8) is a Na+- and Cl--dependent creatine transporter that mediates the transmembrane uptake of creatine, thereby sustaining intracellular creatine pools and cellular energy homeostasis. Dysregulated expression and function of SLC6A8 have been linked to creatine transporter deficiency (CTD), multiple malignancies, diabetes, obesity, and heart failure, underscoring its promising potential as a therapeutic target. Conventional creatine supplementation yields limited therapeutic be…
Rank30.0
Preclinical or laboratory study
Biochimica et biophysica acta. General subjects · 2026 · PMID 42297308
This study investigates the anticancer effects of attenuatumione D, a bioactive compound derived from Hypericum sampsonii Hance, and its potential to inhibit the proliferation of hepatocellular carcinoma (HCC). For this purpose, we employed an in vitro study to assess the cytotoxicity of attenutumione D by measuring cell viability, oxidative stress, and pro-inflammatory cytokine levels using ELISA, as well as apoptosis using flow cytometry and Western blot in HepG2 cells. While in vivo analysis was carried out usin…
Rank30.0
Preclinical or laboratory study
International immunopharmacology · 2026 · PMID 42302375
BACKGROUND: Immune checkpoint inhibitors (ICIs) show promise in hepatocellular carcinoma (HCC) treatment, but clinical responses remain limited due to immune evasion. CD8+ T-cell dysfunction is a key mechanism of immune evasion in HCC. Interferon-stimulated gene 15 (ISG15), a ubiquitin-like modifier, is implicated in tumor progression, but its role in immune suppression in HCC is unclear.
METHODS: ISG15 expression was analyzed in the TCGA-LIHC cohort, and its correlation with prognosis, immune infiltration, and che…
Rank30.0
Preclinical or laboratory study
Neoplasia (New York, N.Y.) · 2026 · PMID 42302326
Endoplasmic reticulum (ER) stress contributes to hepatocellular carcinoma (HCC) progression and promotes the development of a pro-tumorigenic microenvironment. Here, we demonstrate that selective inhibition of the ER-stress sensor PERK using AMG-PERK substantially restrains tumor development when administered during early carcinogenesis in a chemically induced HCC model. PERK inhibition reduced tumor burden, proliferation, and cell viability in vivo, and impaired the growth of HCC cells and patient-derived organoid…
Rank30.0
Preclinical or laboratory study
Toxicology and applied pharmacology · 2026 · PMID 42303055
Hepatocellular carcinoma (HCC) is a type of highly prevalent malignancy characterized by poor prognosis and high rates of recurrence and metastasis. Corynoxine (Cory), a natural alkaloid extracted from Uncaria rhynchophylla, has been identified as an autophagy enhancer. Nevertheless, the biological function of Cory in HCC is yet to be determined. This study aimed to investigate the anti-tumor effects and underlying mechanisms of Cory in HCC using HepG2 and Huh7 cell lines, as well as a xenograft mouse model. Our re…
Rank30.0
Preclinical or laboratory study
Bioorganic chemistry · 2026 · PMID 42442295
Vascular endothelial growth factor receptor-2 (VEGFR-2) is a pivotal therapeutic target in combatting tumor angiogenesis and hepatocellular carcinoma (HCC). In the current research, new indolin-2-one and isoindoline-1,3-dione derivatives were prepared as a part of lead optimization strategy, guided by the reported pharmacophoric features of type-II VEGFR-2 inhibitors. Biological evaluation over six human cancer cell lines identified compounds 5, 6a, 6b, 6e, and 6f as potent cytotoxic agents, exhibiting outstanding …
Rank30.0
Preclinical or laboratory study
Genes & diseases · 2026 · PMID 42306650
Our previous preclinical study determined artesunate as a candidate drug for hepatocellular carcinoma (HCC) and identified glucosylceramidase (GBA) as one of its direct targets. This research aimed to identify the binding sites of GBA with artesunate and the potential anti-HCC mechanisms, which remain unclear. Artesunate effectively suppressed cell viability and proliferation, and enhanced apoptosis of HCC cell lines with more sensitivity in HepG2 than MHCC-97H cells. Network calculation and a series of in vivo and…
Rank30.0
Preclinical or laboratory study
Molecular medicine reports · 2026 · PMID 42429151
Hepatocellular carcinoma (HCC) remains a major global health burden, characterized by limited therapeutic options and poor prognosis. The present study aimed to evaluate the anticancer potential of leonurine, a natural alkaloid derived from Leonurus japonicus, in HCC. Through an integrated approach of network pharmacology and experimental validation, the PI3K/AKT signaling pathway was identified as a key therapeutic target of leonurine. In vitro experiments demonstrated that leonurine dose‑dependently inhibited HCC…
Rank30.0
Preclinical or laboratory study
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2026 · PMID 42476098
Sorafenib resistance remains a major challenge in the treatment of hepatocellular carcinoma (HCC). Through an in vivo CRISPR/Cas9 screen, we identified protein SUMOylation as a key pathway enriched in sorafenib-resistant HCC tumors. SUMO1 expression was significantly upregulated in resistant tumors and cell lines, and its modulation directly influenced sorafenib sensitivity both in vitro and in vivo. Proteomic analysis revealed that SUMO1 overexpression enhanced glycolysis, and metabolic assays confirmed increased …
Rank30.0
Preclinical or laboratory study
Biochemical and biophysical research communications · 2026 · PMID 42378857
Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide. Although CAR-NK cell therapies have shown promise in hematologic malignancies, their efficacy in solid tumors like HCC is often limited by antigen escape. Here, we investigated a dual-targeting strategy combining GPC3 CAR-NK cells with the B7H3-blocking monoclonal antibody Enoblituzumab. We confirmed GPC3 and B7H3 co-expression in HCC tissues and cell lines via database analysis and flow cytometry. GPC3 CAR-NK cells were generated from…
Rank30.0
Preclinical or laboratory study
European journal of medicinal chemistry · 2026 · PMID 42068639
The overexpression of the transcriptional enhanced associate domain (TEAD), which regulates gene transcription linked to cell growth, drives the proliferation in cases of hepatocellular carcinoma (HCC). In order to discover novel TEAD inhibitors that are more effective and have better efficacy and pharmacokinetic properties for treating HCC, this study employed a cyclization strategy to generate a novel indole-based scaffold of TEAD inhibitors. A comprehensive and systematic structure-activity relationship (SAR) an…
Rank30.0
Preclinical or laboratory study
Molecular therapy. Nucleic acids · 2026 · PMID 42440881
Primary liver cancer is the sixth most prevalent cancer globally and is often diagnosed late, when treatment options are limited. Secondary liver cancer, arising from metastasis of other cancers to the liver, is a common complication of advanced solid cancers and a significant cause of cancer-related morbidity and mortality. Existing treatment options for advanced primary and secondary liver tumors have limited efficacy, and new treatment modalities have the potential to improve patient outcomes. Messenger RNA (mRN…
Rank30.0
Preclinical or laboratory study
Biochemical and biophysical research communications · 2026 · PMID 42407434
BACKGROUND: Acquired resistance to sorafenib remains a major obstacle to effectively treating advanced hepatocellular carcinoma (HCC). Ferroptosis has emerged as a key mechanism influencing therapeutic response. EGF-containing fibulin extracellular matrix protein 1 (EFEMP1) contributes to sorafenib resistance in HCC cells by regulating ferroptosis, but its upstream regulatory mechanisms remain elusive.
METHODS: Potential E3 ligases for EFEMP1 were screened using the UbiBrowser database. Protein interactions were va…
Promising Experimental Therapies60 records
Rank110.0
Clinical guideline or consensus statement
Journal of hepatology · 2026 · PMID 42191458
Steatotic liver disease (SLD) comprises a heterogeneous group of liver diseases defined by pathological hepatic lipid accumulation with varying degrees of steatohepatitis and progressive fibrosis, which may culminate in cirrhosis and/or hepatocellular carcinoma. SLD encompasses metabolic dysfunction-associated steatotic liver disease (MASLD), formerly called non-alcoholic fatty liver disease (NAFLD); MetALD, describing patients with MASLD consuming moderately high amounts of alcohol; and alcohol-associated/related …
Rank96.7
Randomized controlled trial
The lancet. Gastroenterology & hepatology · 2026 · PMID 42330996
BACKGROUND: Patients with unresectable hepatocellular carcinoma have a poor prognosis and treatments with long-term benefits are needed. Anti-PD-L1 or anti-PD-1 plus anti-VEGF or anti-CTLA-4 double combinations are validated, first-line, systemic immunotherapies. We report the preplanned phase 2 results of the phase 2-3 PRODIGE 81-FFCD 2101-TRIPLET-HCC trial investigating the survival outcomes and safety profile of a triple combination of atezolizumab, bevacizumab, and ipilimumab in a first-line setting.
METHODS: T…
Rank91.4
Randomized clinical study
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 42008357
PURPOSE: Immune checkpoint inhibitors (ICI) can induce long-term survival and even cancer cure in several cancers. Mixture cure models (MCM) estimate the fraction of long-term survivors and cured patients but have not been applied in hepatocellular carcinoma (HCC).
EXPERIMENTAL DESIGN: We identified phase III randomized trials of first-line ICI in advanced HCC with mature follow-up (≥30 months) and analyzed a cohort of patients with HCC treated with atezolizumab-bevacizumab. After reconstructing Kaplan-Meier curves…
Rank83.1
Phase II clinical trial
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 42126314
PURPOSE: Evidence for radiotherapy (RT) in oligoprogressive hepatocellular carcinoma (OP-HCC) is limited. We evaluated the efficacy and safety of progression-directed RT (PDRT) alongside ongoing first-line systemic therapy (FLST) in patients with OP-HCC.
PATIENTS AND METHODS: Patients who developed OP-HCC during FLST were enrolled and received PDRT with a biologically effective dose of at least 60 Gy while continuing FLST. The primary endpoint was progression-free survival (PFS); secondary endpoints were overall su…
Rank80.1
Phase II clinical trial
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2026 · PMID 42385524
AIMS: It is controversial whether monotherapy with immunotherapeutics is effective in early-stage hepatocellular carcinoma (HCC). We evaluated immunotherapy monotherapy as an initial neoadjuvant strategy.
METHODS: This prospective, single-arm, phase II trial of an adaptive neoadjuvant strategy enrolled patients with resectable, early-stage HCC. All patients received tislelizumab monotherapy; non-responders received subsequent lenvatinib combination therapy preoperatively.
RESULTS: For the overall efficacy of all 36…
Rank79.5
Phase II clinical trial
European journal of cancer (Oxford, England : 1990) · 2026 · PMID 42284972
BACKGROUND: Combinations of anti-angiogenic agents, including lenvatinib, and PD-1/PD-L1 inhibitors have demonstrated antitumor activity with manageable toxicity in several tumor types, including hepatocellular carcinoma (HCC).
OBJECTIVE: The IMMUNIB trial aimed to evaluate efficacy of nivolumab in combination with lenvatinib as first-line treatment in patients with unresectable HCC.
DESIGN: This investigator-initiated single-arm phase-2 trial enrolled patients with advanced stage HCC for first-line therapy who wer…
Rank77.0
Phase II clinical trial
Journal of hepatology · 2026 · PMID 41763363
BACKGROUND & AIMS: Liver transplantation (LT) is a curative treatment option in early and intermediate hepatocellular carcinoma (HCC) following downstaging with locoregional therapies (LRT). Tumor response to immune checkpoint inhibitors may extend LT eligibility to intermediate and advanced stages.
METHODS: In this prospective phase II study, patients with intermediate and advanced HCCs beyond extended transplant criteria, not amenable to further LRTs, were downstaged with atezolizumab-bevacizumab (Atezo-Bev) prio…
Rank66.8
Phase I clinical trialResult signal: benefit
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 41984885
PURPOSE: Although immunotherapy regimens have significantly improved treatment options for patients with advanced hepatocellular carcinoma (HCC), the optimal use of these regimens in earlier disease stages remains poorly defined.
PATIENTS AND METHODS: We conducted a single-institution, single-arm pilot study (NCT04857684) of neoadjuvant stereotactic body radiotherapy (SBRT) followed by 2 cycles of atezolizumab plus bevacizumab and subsequent surgical resection in patients with initially resectable HCC (n = 8). The …
Rank51.5
Other PubMed-indexed publicationResult signal: benefit
Journal for immunotherapy of cancer · 2026 · PMID 42336655
PURPOSE: Liver metastases (LMs) confer resistance to immune checkpoint blockade in advanced non-squamous non-small cell lung cancer (ns-NSCLC), likely through an immunosuppressive tumor microenvironment (TME). We hypothesized that vascular endothelial growth factor (VEGF)-A blockade, by remodeling the immunosuppressive TME, could restore the benefit of chemoimmunotherapy in LM+ patients. Here, we report the first comparative analysis of chemoimmunotherapy with and without bevacizumab specifically in this population…
Rank49.1
Other PubMed-indexed publication
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 41973053
PURPOSE: Resection of liver metastases improves survival in patients with metastatic colorectal cancer (mCRC) with liver-limited disease (LLD), but relapse remains common. Postresection circulating tumor DNA (ctDNA) is a valid prognostic biomarker; however, no data are available regarding the prognostic effect of presurgery ctDNA after upfront chemotherapy.
EXPERIMENTAL DESIGN: Patients (N = 116) with initially unresectable mCRC with LLD who underwent resection after upfront chemotherapy were included. Patients wer…
Rank47.0
Other PubMed-indexed publication
Journal of clinical laboratory analysis · 2026 · PMID 42403196
OBJECTIVE: This study aimed to investigate the expression patterns and prognostic significance of insulin-like growth factor-binding protein 3 (IGFBP3) in hepatocellular carcinoma (HCC) and other cancer types.
METHODS: IGFBP3 expression was analyzed using The Cancer Genome Atlas (TCGA)-LIHC, International Cancer Genome Consortium (ICGC-LIRI-JP), Gene Expression Omnibus (GEO; GSE102079 and GSE112790), and Genotype-Tissue Expression (GTEx) databases. Experimental validation included immunohistochemistry (IHC) and qua…
Rank45.0
Other PubMed-indexed publication
PLoS computational biology · 2026 · PMID 42330082
The crosstalk between lactylation and autophagy within the hepatocellular carcinoma (HCC) microenvironment is a burgeoning field with profound implications. By integrating multi-omics data from public cohorts, we delineated two molecular subtypes of HCC with divergent clinical outcomes and established a lactylation-autophagy-related prognostic signature. This signature highlighted CLEC3B as a pivotal gene. Subsequent single-cell RNA sequencing and experimental validation unequivocally pinpointed liver sinusoidal en…
Rank45.0
Other PubMed-indexed publication
PeerJ · 2026 · PMID 42369747
Conflict between humans and carnivores, known as Human-Carnivore Conflict (HCC), has existed throughout history, with recent escalations attributed to anthropogenic expansion and intensified resource competition. Conflict with carnivores primarily stems from livestock depredation, resulting in economic losses that threaten livelihoods. These conflicts pose significant challenges for affected human communities and carnivore conservation. Non-lethal mitigation strategies, particularly livestock guardian animals (LGAs…
Rank45.0
Other PubMed-indexed publication
International journal of molecular sciences · 2026 · PMID 42449971
Hepassocin, also known as fibrinogen-like protein 1 (FGL-1), is a liver-derived secretory protein initially identified as a mitogenic factor involved in hepatocyte proliferation and liver regeneration. Increasing evidence has subsequently suggested that FGL-1 functions as a hepatokine linking hepatic metabolic stress to systemic metabolic regulation. Experimental and clinical studies have demonstrated that circulating FGL-1 levels are associated with obesity, insulin resistance, metabolic dysfunction-associated ste…
Rank45.0
Other PubMed-indexed publication
Molecular biology reports · 2026 · PMID 42377685
BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most common causes of death around the world, and it is commonly diagnosed late, so systemic chemotherapy is commonly used. Lysosomal sequestration of chemotherapy drugs such as sorafenib [1] decreases the effective concentration of chemotherapy at the target sites and leads to chemoresistance, also chemoresistance may arise from autophagy activation. We aimed to find a new therapeutic regimen for HCC through enhancing the chemosensitivity of SB by combining …
Rank45.0
Other PubMed-indexed publication
Hepatology (Baltimore, Md.) · 2026 · PMID 39808821
Preventive interventions are expected to substantially improve the prognosis of patients with primary liver cancer, predominantly HCC and cholangiocarcinoma. HCC prevention is challenging in the face of the evolving etiological landscape, particularly the sharp increase in obesity-associated metabolic disorders, including metabolic dysfunction-associated steatotic liver disease. Next-generation anti-HCV and HBV drugs have substantially reduced, but not eliminated, the risk of HCC and have given way to new challenge…
Rank45.0
Other PubMed-indexed publication
Biomaterials · 2026 · PMID 41619660
Chronic hypoxia is a critical barrier to the effective treatment of solid tumors, including hepatocellular carcinoma (HCC), as it not only restricts the oxygen supply required for sonodynamic therapy (SDT) but also upregulates hypoxia-inducible factor-2α (HIF-2α), thereby accelerating tumor progression, inducing abnormal angiogenesis, suppressing antitumor immune responses, and diminishing the efficacy of targeted therapies. Here, we developed an intelligent switchable organic-inorganic hybrid nanoplatform (VitK3/P…
Rank45.0
Other PubMed-indexed publication
Medicine · 2026 · PMID 42332510
Hepatocellular carcinoma (HCC) is a malignancy with a poor prognosis and low overall survival. Tuoli Xiaozheng Formula (TLXZF), a traditional Chinese compound prescription, has shown clinical efficacy in treating HCC, but its multi-component and multi-target mechanisms remain unclear. This study aimed to elucidate the molecular mechanisms of TLXZF against HCC by integrating network pharmacology, molecular docking, and Mendelian randomization (MR) analyses. Active compounds and targets were identified from the Tradi…
Rank45.0
Other PubMed-indexed publication
Critical reviews in oncology/hematology · 2026 · PMID 42086130
Secondary resistance remains a major clinical hurdle in advanced hepatocellular carcinoma (HCC), despite the paradigm shift toward combining tyrosine kinase inhibitors (TKIs) with immune checkpoint inhibitors (ICIs). Existing literature largely focuses on static microenvironmental factors or tumor-intrinsic mutations. The potential role of efferocytosis-driven metabolic reprogramming as a theoretical link between TKI-induced cell death and immune tolerance remains a critical conceptual gap. Addressing this gap, thi…
Rank45.0
Other PubMed-indexed publication
Journal of the American Chemical Society · 2026 · PMID 42225312
Nucleotide bases encode genetic information through specific structural arrangements. Their abnormalities in structure and composition, such as gene mutations and epigenetic modifications, can trigger multiple diseases. Precise discrimination of bases is critical yet challenging due to their high structural similarity. Herein, we report triphenylamine-based covalent organic framework nanosheets (TPA CONs) as a fluorescent biosensor for nucleobase discrimination and deoxyribonucleic acid (DNA) methylation quantitati…
Rank45.0
Other PubMed-indexed publication
Liver international : official journal of the International Association for the Study of the Liver · 2026 · PMID 42188461
Liver fibrosis is a shared pathological phenotype of chronic liver diseases of diverse etiologies, including viral hepatitis, alcohol-associated liver disease and metabolic dysfunction-associated steatohepatitis (MASH), as well as cholestatic liver diseases such as primary biliary cholangitis and primary sclerosing cholangitis, and may progress to cirrhosis, hepatic decompensation and hepatocellular carcinoma. Despite advances in etiological treatments, effective therapies for established fibrosis remain limited. I…
Rank45.0
Other PubMed-indexed publication
Journal of biochemical and molecular toxicology · 2026 · PMID 42346026
Hepatocellular carcinoma (HCC) is an aggressive cancer with poor prognosis and high mortality rates. The increasing mortality associated with HCC highlights the urgent need for alternative therapeutic approaches. Natural products and their structural analogs have shown promise as novel treatment options. This study aimed to evaluate the potential therapeutic effects of the natural flavonoids apigenin and chrysin, administered individually and in combination, in an experimental HCC model. Forty-eight rats were divid…
Rank45.0
Other PubMed-indexed publication
In vivo (Athens, Greece) · 2026 · PMID 42379766
BACKGROUND/AIM: Expanding the ablation area remains a critical challenge in the treatment of hepatocellular carcinoma. Herein, we investigated the utility of various radiofrequency ablation (RFA) protocols for increasing ablation areas, using the bovine liver as a model.
MATERIALS AND METHODS: A bovine liver (7.2 kg) placed in a stainless-steel tray was subjected to RFA using an arfa 17-G electrode. The starting and increment wattages were varied in the linear mode. RFA was stopped after one break. The size of the …
Rank45.0
Other PubMed-indexed publication
Journal of medical virology · 2026 · PMID 42478159
Chimpanzees are the only non-human species susceptible to hepatitis C virus (HCV) infection and have served as models in HCV pathogenesis and antiviral drug development. Despite this, the long-term clinical consequences of chronic infection and therapeutic efficacy of direct-acting antivirals (DAAs) in this species are poorly documented. We evaluated the virologic, biochemical, and clinical outcomes of DAA therapy in eight captive chimpanzees with experimental HCV infection, with a median infection duration of 36 y…
Rank45.0
Other PubMed-indexed publication
Nutrients · 2026 · PMID 42514283
Introduction: Hepatic fibrosis represents a critical intermediate stage in the progression from chronic liver disease to cirrhosis and ultimately hepatocellular carcinoma. Spirulina platensis, a microorganism rich in bioactive compounds, contains several functional components, among which are Spirulina polysaccharides and phycocyanin. Both have been demonstrated to exhibit multiple biological activities, including antioxidant, anti-inflammatory, and immunomodulatory effects. However, the intervention effects and me…
Prospective Cohort Studies115 records
Rank107.6
Systematic review or meta-analysis
JAMA network open · 2026 · PMID 42084869
IMPORTANCE: Circadian rhythms affect immunity, which could affect the effectiveness of immune checkpoint inhibitor (ICI). Whether the time of ICI administration is associated with clinical outcomes in advanced cancers remains unclear.
OBJECTIVE: To evaluate the association between time of day of ICI administration and oncologic outcomes in patients with advanced solid tumors.
DATA SOURCES: MEDLINE (via PubMed), Embase, and Web of Science Core Collection were searched in February 2026 to identify eligible studies.
S…
Rank104.1
Systematic review or meta-analysis
Journal of gastrointestinal cancer · 2026 · PMID 42213206
BACKGROUND: Liver transplantation (LT) has emerged as a potential treatment option for selected patients with colorectal liver metastases (CRLM), but existing meta-analyses are limited by heterogeneous populations and mixed treatment modalities.
METHODS: A systematic review and single-arm meta-analysis were conducted in accordance with PRISMA guidelines. Studies reporting outcomes following LT for CRLM were included. Primary outcomes were overall survival (OS) and progression-free survival (PFS) at predefined time …
Rank101.2
Systematic review or meta-analysisResult signal: harm
JAMA network open · 2026 · PMID 42268607
IMPORTANCE: Artificially sweetened beverages (ASBs) and sugar-sweetened beverages (SSBs) are widely consumed worldwide and have been linked to metabolic disorders, including obesity and type 2 diabetes, which are established risk factors associated with liver cancer. However, prospective evidence examining beverage consumption and liver cancer subtypes remains limited and inconsistent.
OBJECTIVE: To examine associations between ASB and SSB consumption and risk of incident liver cancer overall and by subtype, includ…
Rank100.0
Systematic review or meta-analysis
Cancer medicine · 2026 · PMID 41717812
BACKGROUND AND AIMS: This study aimed to evaluate the clinical efficacy of particle therapy for hepatocellular carcinoma (HCC) by integrating a prospective registry and a systematic meta-analysis. Our findings also reflect the real-world impact of this evidence, which contributed to the national health insurance approval of particle therapy for HCC tumors ≥ 4 cm in Japan.
METHODS: Patients who received particle therapy for HCC from May 2016 to June 2018 were registered. Ninety studies (25 particle therapy, 26 non-S…
Rank96.0
Randomized controlled trialResult signal: null
Cardiovascular and interventional radiology · 2026 · PMID 41572025
PURPOSE: To compare the patency outcomes and safety profile between the modified TR Band and the PreludeSYNC DISTAL (PSD) for hemostasis following distal transradial access (dTRA) for transarterial chemoembolization (TACE).
METHODS: This prospective randomized trial enrolled 104 participants undergoing TACE via dTRA (143 procedures, all performed using a 4-Fr catheter. Participants achieved hemostasis with either the modified TR Band (n = 74) or PSD (n = 69). The primary endpoint was the incidence of radial artery …
Rank95.0
Randomized controlled trialResult signal: benefit
Journal of translational medicine · 2025 · PMID 40702551
BACKGROUND: Transarterial chemoembolization (TACE) is commonly used to treat patients with unresectable hepatocellular carcinoma (HCC); however, TACE alone has demonstrated unsatisfactory survival benefits. Our previous studies suggested that TACE plus oral medication of thalidomide, carmofur and compound mylabris capsule (TCC cocktail) may be a better therapeutic option.
METHODS: In this randomized, open-label, multicenter clinical trial, 72 treatment-naive HCC patients were randomly assigned to receive cTACE alon…
Rank92.4
Randomized clinical study
Langenbeck's archives of surgery · 2026 · PMID 42307778
BACKGROUND: Posthepatectomy liver failure (PHLF) remains the most lethal complication after liver resection. This study aimed to identify preoperative and intraoperative risk factors for PHLF following open hepatectomy using data derived from prospective clinical trials.
METHODS: A pooled secondary analysis of five prospective studies - four randomized controlled trials and one prospective cohort study - was performed, including 515 patients who underwent elective open liver resection between 2007 and 2017 at two h…
Rank89.2
Randomized clinical study
BMJ open · 2026 · PMID 42493202
INTRODUCTION: Liver resection is a technically demanding procedure due to the complex and highly variable anatomy of the liver. Conventional preoperative planning relies on two-dimensional imaging, which requires mental reconstruction of three-dimensional anatomical relationships and may increase cognitive workload and intraoperative decision-making time. Patient-specific three-dimensional (3D) liver mapping has been shown to improve anatomical understanding and planning accuracy; however its impact on intraoperati…
Rank89.2
Randomized clinical study
BMJ open · 2026 · PMID 42264528
INTRODUCTION: Treatment options remain limited for patients with advanced hepatocellular carcinoma (HCC) who experience oligoprogression during first-line systemic therapy (FLST), especially given the modest efficacy and restricted availability of second-line systemic therapy (SLST). This trial aims to evaluate whether continuing FLST combined with radiotherapy (RT) to oligoprogressive lesions can improve progression-free survival (PFS) compared with an early switch to SLST in patients with oligoprogressive HCC whi…
Rank88.0
Randomized clinical study
Cancer medicine · 2024 · PMID 38629255
BACKGROUND: More than half of neuroendocrine tumor (NET) patients will experience liver metastasis, and interventional therapy represented by transarterial embolization (TAE) is the main local treatment method. Surufatinib is recommended as a standard systemic treatment for advanced NETs. The efficacy and safety of surufatinib combined with TAE in the treatment of liver metastasis are undetermined. This study was conducted to compare the clinical outcome of surufatinib combined with TAE versus surufatinib monothera…
Rank88.0
Phase III clinical trial
Radiology · 2026 · PMID 41874299
Background Real-time methods are needed for intraprocedural detection of residual tumors and incomplete thermal ablation (TA) to allow immediate retreatment and tumor eradication. Purpose To validate a TA workflow for detecting and immediately ablating residual viable colorectal liver metastases (CLMs). Materials and Methods This prospective single-center trial enrolled participants who underwent PET/CT-guided microwave CLM ablation from November 2019 to February 2023. The minimal ablation margin (MM) was calculate…
Rank82.4
Multicenter clinical study
Radiology · 2026 · PMID 42117996
Background Intratumoral fibrosis (ITF) may influence the prognosis of hepatocellular carcinoma (HCC) and transarterial chemoembolization (TACE) efficacy. However, pretreatment biopsies are not routinely performed for HCC. Purpose To develop and validate a CT-based radiomics model to classify ITF grade in HCC and to evaluate the associations of model ITF classifications with post-TACE prognosis and tumor angiogenesis levels. Materials and Methods This multicenter study (August 2013 to November 2023) included five re…
Rank81.0
Multicenter clinical study
Alimentary pharmacology & therapeutics · 2026 · PMID 42017265
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) exhibits marked heterogeneity in fibrosis progression and liver-related outcomes. Liver biopsy is not feasible for longitudinal risk stratification at scale, creating a need for validated non-invasive biomarkers, particularly imaging biomarkers, that can predict clinically meaningful disease progression and liver-related outcomes.
AIMS: To describe the design and rationale of the GOLDMINE study, established to determine whether non-invasiv…
Rank80.1
Phase II clinical trial
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2026 · PMID 42385524
AIMS: It is controversial whether monotherapy with immunotherapeutics is effective in early-stage hepatocellular carcinoma (HCC). We evaluated immunotherapy monotherapy as an initial neoadjuvant strategy.
METHODS: This prospective, single-arm, phase II trial of an adaptive neoadjuvant strategy enrolled patients with resectable, early-stage HCC. All patients received tislelizumab monotherapy; non-responders received subsequent lenvatinib combination therapy preoperatively.
RESULTS: For the overall efficacy of all 36…
Rank79.8
Multicenter clinical study
European radiology · 2026 · PMID 42053592
OBJECTIVES: Transarterial chemoembolization (TACE) is a promising locoregional therapy for unresectable colorectal liver metastases, but patient selection remains challenging. We aimed to develop and validate prognostic radiomics-based machine learning models in a multicenter, prospectively collected drug-eluting microsphere TACE cohort.
MATERIALS AND METHODS: We retrospectively analyzed 76 patients (176 lesions) from the prospective CIREL registry trial. Radiomic features were extracted from each lesion. We tested…
Rank79.5
Multicenter clinical study
Annals of surgical oncology · 2026 · PMID 41926013
BACKGROUND: Enhanced recovery programs (ERPs) improve short-term outcomes after liver surgery (LS), but their impact on survival remains uncertain. This study evaluated the association between ERP compliance and survival in a large multicenter cohort.
METHODS: This prospective European multicenter cohort included adults undergoing elective LS between 2016 and 2024 in 10 centers implementing Enhanced Recovery After Surgery (ERAS)-consistent ERPs. Compliance was defined as the proportion of 21 fulfilled items with hi…
Rank79.5
Multicenter clinical studyResult signal: benefit
Molecular biomedicine · 2026 · PMID 41807813
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality, with significantly improved prognosis when detected early in high-risk populations. Current serum biomarkers show limited sensitivity for early-stage disease. We developed and validated GAMAD, a multimodal diagnostic model integrating circulating tumor DNA (ctDNA) methylation with established serum markers to enhance early HCC detection in China. In this multicenter prospective trial, a total of 1,692 patients were enrolled: 476 wit…
Rank79.4
Multicenter clinical study
Gut · 2026 · PMID 41911049
BACKGROUND: Current guidelines recommend a two-step approach for risk stratification of metabolic dysfunction-associated steatotic liver disease (MASLD), starting with Fibrosis-4 index (FIB-4) followed by liver stiffness measurement (LSM) using vibration-controlled transient elastography (VCTE).
OBJECTIVE: To evaluate this approach for predicting advanced fibrosis and liver-related events (LREs) in patients with type 2 diabetes (T2D).
DESIGN: A prospective liver biopsy cohort of T2D patients with histologically con…
Rank79.4
Phase II clinical trial
Cancer letters · 2025 · PMID 40962045
Ultrasound triggered microbubble destruction (UTMD) has been shown to sensitize tumors to radiation. This study evaluated the feasibility, safety, and efficacy of using UTMD for radiosensitization in participants with intrahepatic cholangiocarcinoma (ICC) and/or metastatic disease to the liver (MDL) receiving Yttrium-90 transarterial radioembolization (Y90-TARE). This was a prospective single-center IRB-approved clinical trial. Participants received four contrast ultrasound sessions: 1-2 weeks prior to Y90-TARE, 1-…
Rank79.1
Multicenter clinical study
Clinical and translational medicine · 2026 · PMID 42145083
BACKGROUND AND AIMS: Existing imaging and serum-marker assays miss many early liver cancers, especially in high-risk chronic liver disease carriers. We aimed to create a highly accurate, non-invasive, methylation-based liquid biopsy for early detection.
METHODS: We used a comprehensive, multi-platform, multi-cohort strategy for marker discovery, starting with methylation profiling of hepatocellular carcinoma samples from TCGA and in-house cohorts. From 30 initial candidates, nine highly liver-specific methylation m…
Rank77.7
Multicenter clinical study
BMJ open · 2026 · PMID 42486514
INTRODUCTION: Hepatocellular carcinoma is the sixth most common malignancy worldwide, with immune checkpoint inhibitors transforming treatment paradigms despite modest response rates of approximately 30%. Emotional distress, encompassing depression and anxiety symptoms, affects 30-50% of cancer patients and may influence immunotherapy efficacy through immune system modulation. Recent studies in lung cancer, gastric cancer and melanoma demonstrate associations between pretreatment emotional distress and worse immuno…
Rank77.6
Multicenter clinical study
Future oncology (London, England) · 2025 · PMID 40662675
AIM: Asia-Pacific guidelines recommend selective internal radiation therapy (SIRT) as an alternative to transarterial chemoembolization for patients with intermediate or advanced hepatocellular carcinoma (HCC) and, in more limited circumstances, for metastatic colorectal cancer (mCRC). This multicenter, single-arm, prospective, observational registry evaluated safety and efficacy of SIRT with 90Y resin microspheres for HCC or mCRC in Asia.
PATIENTS & METHODS: Adults (n = 202) with HCC or mCRC eligible for, and sche…
Rank77.4
Multicenter clinical study
European journal of gastroenterology & hepatology · 2025 · PMID 40801208
BACKGROUND: The burden of hepatocellular carcinoma (HCC) increases worldwide. We report the current landscape of HCC, in France.
METHODS: Carcinome HépatocellulaIrE en France (CHIEF) is a national, prospective, observational cohort initiated in 2019 with the aim of including 5000 patients with HCC, with a 5-year follow-up for each. CHIEF Epidemio 2000, is the first global analysis.
RESULTS: In September 2021, 2043 patients were included in 32 centers. We analyzed 1640 patients, 86% men, 68-year-old, BMI 26.8. 70.8%…
Rank77.3
Multicenter clinical study
Ultrasound in medicine & biology · 2026 · PMID 41934080
OBJECTIVE: Given the high hypoenhancement prevalence of hepatic hemangiomas (HHs) during the transitional phase and Kupffer phase (KP) of Sonazoid contrast-enhanced ultrasound (CEUS), this study aimed to investigate the hypoenhancement phenomenon pattern and its influencing factors.
METHODS: This was a prospective multicenter study. A total of 136 patients with HHs were enrolled from 26 medical centers, including 76 cases in the KP hypoenhancement group and 60 cases in the KP non-hypoenhancement group. Enhancement …
Rank77.2
Multicenter clinical study
Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine · 2026 · PMID 41439463
OBJECTIVE: To investigate the value of transitional phase characteristics on Sonazoid contrast-enhanced ultrasound (S-CEUS) in the differential diagnosis of common focal liver lesions (FLLs).
MATERIALS AND METHODS: This prospective multicenter study enrolled 122 participants with FLLs from 8 medical centers between December 2023 and March 2025. The study comprised 43 cases of hepatic hemangioma (HH), 35 cases of hepatocellular carcinoma (HCC), and 44 cases of liver metastases (LM). All participants underwent standa…
Quality Of Life100 records
Rank107.9
Systematic review or meta-analysis
Frontiers in oncology · 2026 · PMID 42222418
OBJECTIVE: To assess the reporting characteristics and quality of patient-reported outcomes (PROs) in randomized controlled trials (RCTs) of targeted therapy and/or immunotherapy for liver cancer.
METHODS: We systematically searched six electronic databases for relevant RCTs published in English or Chinese from inception to April 17, 2025. The reporting quality of PROs was assessed using the CONSORT-PRO extension and the CONSORT 2010 guidelines.
RESULTS: We included 64 RCTs with 8,494 participants. Of these, 14 stu…
Rank104.9
Systematic review or meta-analysis
Journal of bone oncology · 2026 · PMID 42388270
BACKGROUND: Surgery for long bone metastases is performed to alleviate pain, restore function, and improve quality of life. Accurate postoperative survival estimates are essential for surgical planning and shared decision-making, yet no comprehensive synthesis exists across primary tumor types. This systematic review aimed to characterize postoperative survival and its temporal trend in patients undergoing surgery for long bone metastases.
METHODS: A systematic literature search was performed in PubMed, EMBASE, and…
Rank104.5
Systematic review or meta-analysisResult signal: null
World journal of surgical oncology · 2026 · PMID 42050547
BACKGROUND: Transarterial radioembolization (TARE) is increasingly used as an alternate and potentially superior treatment option to Transarterial chemoembolization (TACE) for early- to intermediate-stage unresectable hepatocellular carcinoma (HCC). However, randomized controlled trials (RCTs) comparing the two modalities have reported mixed findings, and the comparative efficacy and safety remain uncertain. METHODS: A comprehensive literature search was conducted across five databases until August 2025, following …
Rank103.8
Systematic review or meta-analysis
Critical reviews in oncology/hematology · 2026 · PMID 42250662
BACKGROUND: Immunotherapy-based regimens are standard first-line treatments for advanced hepatocellular carcinoma (HCC), yet integrated comparisons across efficacy, safety, and quality-of-life (QoL) outcomes remain limited. We performed a network meta-analysis (NMA) to identify the optimal treatment strategy.
METHODS: A literature search was conducted in PubMed, Embase, Cochrane Library, and Scopus to identify phase III randomized controlled trials (RCTs) evaluating immune checkpoint inhibitor (ICI)-based therapies…
Rank103.6
Systematic review or meta-analysis
Frontiers in immunology · 2026 · PMID 41743719
INTRODUCTION: Despite the growing arsenal of novel anti-tumor drugs for digestive system cancers, concerns persist regarding their true clinical value, as approvals often rely on surrogate endpoints with limited overall survival or quality of life data. This study systematically evaluates the clinical benefit of these drugs in China using standardized value assessment frameworks and identify factors associated with high-value treatments.
METHODS: This cross-sectional study analyzed 65 indications from 33 novel anti…
Rank102.7
Systematic review or meta-analysis
Journal of pain research · 2026 · PMID 41868286
BACKGROUND: Approximately 60-80% of patients with advanced liver cancer experience pain, significantly impairing quality of life. While the three-step analgesic regimen has limitations, acupuncture has gained attention for cancer pain management, though evidence for its combined use remains inconsistent. This Bayesian network meta-analysis evaluated the clinical value of acupuncture combined with the three-step regimen.
METHODS: Randomized controlled trials on acupuncture combined with three-step analgesia for live…
Rank101.2
Systematic review or meta-analysis
HPB : the official journal of the International Hepato Pancreato Biliary Association · 2026 · PMID 42436069
BACKGROUND: Histotripsy is an emerging non-thermal, non-invasive focused ultrasound technology. This systematic review aims to evaluate the early clinical safety and efficacy of histotripsy in the treatment of liver malignancies.
METHODS: A systematic search was conducted across Web of Science, Medline, Scopus, and Cochrane CENTRAL up to February 2026. The search strings combined terms for "histotripsy" and "liver tumor/cancer/metastasis". Studies reporting technical success rate or complications of histotripsy for…
Rank99.0
Randomized controlled trial
BMC women's health · 2026 · PMID 41821023
RESEARCH QUESTION: Endometriosis-related chronic pain leads to impaired health-related quality of life (HRQoL). Endometriosis surgery can improve chronic pain and HRQoL, however, pain complaints often remain and HRQoL is still lower compared to that in healthy women. Cognitive behavioral therapy (CBT) is promising for the treatment of chronic pain. In this study we evaluate the effect of CBT on HRQoL in patients undergoing surgery for endometriosis-related chronic pain. DESIGN: This randomized controlled, single-bl…
Rank97.6
Randomized controlled trialResult signal: benefitCorrection flagged
JAMA oncology · 2025 · PMID 39699905
IMPORTANCE: Most patients with locally advanced hepatocellular carcinoma (HCC) recur within the liver following systemic therapy.
OBJECTIVE: To determine whether stereotactic body radiation therapy (SBRT) improves outcomes in patients with locally advanced HCC compared with sorafenib alone.
DESIGN, SETTING, AND PARTICIPANTS: This multicenter phase 3 randomized clinical trial randomized patients with HCC 1:1 to sorafenib or SBRT followed by sorafenib, stratified by performance status, liver function, degree of metas…
Rank96.0
Systematic review or meta-analysis
Systematic reviews · 2026 · PMID 41618440
BACKGROUND: Chronic hepatitis C virus infection presents a substantial global health burden, frequently resulting in severe liver conditions. Hepatitis C virus (HCV) therapy requires complex decision-making. Direct-acting antivirals (DAAs) offer a potential solution by targeting viral proteins to inhibit replication. Understanding DAAs real-world effectiveness and how they impact long-term outcomes beyond clinical trials is essential. We aim to comprehensively evaluate the benefits and harms of DAAs in individuals …
Rank96.0
Systematic review or meta-analysisResult signal: harm
Clinics (Sao Paulo, Brazil) · 2026 · PMID 41720053
OBJECTIVE: This study aimed to explore the efficacy and safety of lenvatinib and sorafenib as first-line treatments for hepatocellular carcinoma.
METHOD: The authors searched PubMed, Web of Science, Cochrane, CNKI, Wanfang, and other databases and compared the clinical efficacy of lenvatinib and sorafenib as first-line treatments for hepatocellular carcinoma. Two participants screened the literature, collated the data, and evaluated the literature according to the inclusion and exclusion criteria. RevMan 5.4 softwa…
Rank92.4
Randomized clinical studyResult signal: benefit
Frontiers in pharmacology · 2026 · PMID 42064805
INTRODUCTION: Huaier granules (HEG), a traditional Chinese medicinal product primarily composed of Trametes robiniophila Murr., have been incorporated into comprehensive treatment strategies for various cancers. When combined with conventional antitumor therapies, it has demonstrated notable adjuvant and synergistic effects, improving quality of life and prolonging survival in patients. This study aimed to systematically review the clinical efficacy, safety, and potential mechanisms of HEG as adjuvant therapy in on…
Rank92.0
Randomized controlled trialResult signal: harm
Danish medical journal · 2026 · PMID 41736646
INTRODUCTION: Heat-based ablation has emerged as a less invasive alternative to surgical resection for primary and metastatic liver cancer. However, when a percutaneous approach is not feasible, ablation during open surgery is often performed. Open surgery may be accompanied by an increased risk of complications, especially in patients with comorbidities or liver cirrhosis. Laparoscopic ablation may reduce morbidity while offering a similar efficacy; however, even so, no randomised studies have been conducted.
METH…
Rank92.0
Randomized controlled trial
Annals of surgery · 2026 · PMID 39523954
BACKGROUND: Postoperative morbidity can reduce the quality of life, physical performance, and tolerability of postoperative chemotherapy in patients with colorectal liver metastases (CRLM). Exercise can improve these outcomes in some cancer populations. However, it remains unknown whether exercise can be delivered in the early postoperative period after surgery for CRLM without increasing the risk of harm.
OBJECTIVE: The primary objective was to compare the number of serious adverse events (SAEs) in exercise interv…
Rank90.9
Randomized clinical study
The American journal of gastroenterology · 2026 · PMID 42262375
INTRODUCTION: Informal caregivers are critical for the care of patients with end-stage liver disease (ESLD), but few studies have examined their impact on patient-reported outcome measures (PROMs). We aimed to describe the association between caregiver involvement, caregiver burden, and PROMs in a large ESLD cohort.
METHODS: We analyzed the palliative care for liver diseases (PAL-LIVER) cluster randomized trial, which compared 2 models of palliative care for ESLD and/or hepatocellular carcinoma at 19 US sites. Pati…
Rank90.7
Randomized clinical study
Journal of pain research · 2026 · PMID 42058818
BACKGROUND: The current method for managing opioid tolerance is opioid rotation, but its effectiveness is limited. Transcutaneous electrical acupoint stimulation (TEAS) combined therapy has been shown to effectively relieve moderate-to-severe pain in patients with hepatocellular carcinoma (HCC), but there is insufficient evidence regarding its role in modulating opioid tolerance. Additionally, exosomal proteomics can aid in exploring the potential mechanisms of action of TEAS.
METHODS: This single-center, patient-b…
Rank90.0
Randomized clinical study
BMC cancer · 2026 · PMID 42143303
BACKGROUND: In patients with colorectal cancer liver metastases (CRLM), resection of the primary tumour and local treatment of liver metastases may offer a chance of cure or long-term survival. Most patients however present with unresectable CRLM. Hepatic arterial infusion pump (HAIP) therapy with floxuridine (FUDR) combined with systemic therapy (SYST) could enhance conversion to resectable CRLM, reduce recurrences and therefore, probably prolong survival. The aim of this trial is to investigate whether intensifyi…
Rank90.0
Randomized clinical study
Trials · 2026 · PMID 42185926
BACKGROUND/AIM: Hepatocellular carcinoma (HCC) and colorectal cancer liver metastases (CRLM) carry high recurrence rates after surgery or transplantation. Conventional imaging and biomarkers have limited sensitivity for detecting minimal residual disease (MRD). Circulating tumor DNA (ctDNA) is a promising biomarker that may enable earlier recurrence detection compared with standard methods. The aim of this randomized controlled trial is to evaluate the clinical utility of ctDNA monitoring in the early detection of …
Rank89.8
Randomized clinical study
BMJ open · 2026 · PMID 42114858
INTRODUCTION: Electronic patient-reported outcome (ePROs)-based symptom monitoring benefits health-related quality of life (HRQoL) in various cancers. However, despite the high disease and economic burden of hepatocellular carcinoma (HCC) and the complex symptom profile during immunotherapy, the effectiveness and implementation of ePROs-based interventions in this population remain unclear. This study aims to evaluate the clinical and implementation outcomes of ePROs-based symptom monitoring among patients with HCC…
Rank89.6
Randomized clinical study
BMJ open · 2026 · PMID 42562579
INTRODUCTION: Primary liver cancers, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma, are one of the leading causes of cancer-related mortality. Transarterial chemoembolisation (TACE) and radioembolisation (TARE) are established palliative treatments yet they are traditionally performed during inpatient hospitalisation. Recent technical and organisational advances allow for safe same-day ambulatory procedures. In particular, the extent to which ambulatory intra-arterial therapy aligns with pa…
Rank89.2
Randomized clinical study
BMJ open · 2026 · PMID 42264528
INTRODUCTION: Treatment options remain limited for patients with advanced hepatocellular carcinoma (HCC) who experience oligoprogression during first-line systemic therapy (FLST), especially given the modest efficacy and restricted availability of second-line systemic therapy (SLST). This trial aims to evaluate whether continuing FLST combined with radiotherapy (RT) to oligoprogressive lesions can improve progression-free survival (PFS) compared with an early switch to SLST in patients with oligoprogressive HCC whi…
Rank89.1
Randomized clinical study
Contemporary clinical trials · 2026 · PMID 42309387
INTRODUCTION: Liver metastases are common in several malignancies, with only 15-20% of patients eligible for surgical resection. For non-surgical candidates, stereotactic body radiation therapy (SBRT) is an effective alternative with acceptable local control (LC) rates. Higher biologically effective doses (BED10 > 100 Gy10) are associated with improved LC, and single-fraction ultra-high dose SBRT (35-40 Gy) has demonstrated excellent LC with minimal toxicity. MR-guided adaptive SBRT enhances precision and may optim…
Rank87.0
Randomized clinical studyResult signal: benefit
Liver cancer · 2026 · PMID 41972014
INTRODUCTION: The CARES-310 randomized, open-label, international phase 3 trial reported improved overall survival and progression-free survival with camrelizumab-rivoceranib compared with sorafenib in adults with unresectable hepatocellular carcinoma (uHCC).
METHODS: We performed a post hoc analysis of data from CARES-310 to evaluate patient-reported outcomes (PROs), survival, and safety in adults <65 years and ≥65 years. PRO endpoints included time to deterioration with a ≥10-point decrease from baseline of healt…
Rank85.0
Randomized clinical study
Therapeutic advances in medical oncology · 2026 · PMID 41732658
BACKGROUND: Immune checkpoint inhibitor (ICI)-based combination therapy has transformed the therapeutic landscape of advanced hepatocellular carcinoma (aHCC). However, durable clinical benefit remains limited to a subset of patients, highlighting the need for approaches that enhance efficacy.
OBJECTIVES: The MONTBLANC study presents a novel investigational strategy utilizing triple immunotherapy through the combination of the anti-programmed cell death ligand 1 antibody durvalumab, the anti-cytotoxic T-lymphocyte-a…
Rank85.0
Randomized clinical study
Nuclear medicine communications · 2026 · PMID 42169550
BACKGROUND: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) demonstrating liver-dominant inoperable metastatic diseases or locally advanced inoperable tumors may at times show reduced efficacy for intravenous peptide receptor radionuclide therapy (PRRT).
AIMS AND OBJECTIVES: To determine and compare the outcome of intra-arterial [ 177 Lu]Lu-DOTATATE PRRT in GEP-NET with locally advanced inoperable primary or liver-dominant metastases who had shown no response after at least two cycles of intravenous [ 177 L…
Randomized Controlled Trials60 records
Rank110.0
Systematic review or meta-analysis
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2026 · PMID 42285810
BACKGROUND AND AIMS: Statins have been proposed as hepatoprotective agents in chronic liver disease (CLD); however, evidence from existing systematic reviews-including observational studies and clinical trials-is inconsistent and affected by substantial overlap. We conducted an umbrella review to synthesize the available evidence on the associations between statin use and hepatological outcomes in CLD patients, while addressing study overlap.
DESIGN: PubMed, EMBASE, and Cochrane Library were searched up to Septembe…
Rank108.7
Systematic review or meta-analysis
Abdominal radiology (New York) · 2026 · PMID 41364225
OBJECTIVES: Hepatocellular adenomas (HCA) are typically resected if > 5 cm after 6 months due to historical risks of bleeding and malignant transformation. Outcomes of contemporary patients managed with surveillance are not well defined. We performed a systematic review and meta-analysis of patients with HCAs monitored for ≥ 6 months to assess rates of size stability, bleeding, and malignant transformation.
METHODS: PubMed, Web of Science, and Embase databases were searched up to August 2025 for all articles report…
Rank108.0
Systematic review or meta-analysis
Frontiers in immunology · 2026 · PMID 42620506
BACKGROUND: Phase III trials of first-line immunotherapy-based combinations for advanced hepatocellular carcinoma (HCC) have yielded heterogeneous results, and head-to-head comparisons remain scarce. We evaluated mechanism-based strategy classes and individual regimens using a dual-level Bayesian network meta-analysis to provide a structured interpretation of the current evidence.
METHODS: We systematically searched the literature up to December 28, 2025, and identified 15 phase III randomised controlled trials. A …
Rank108.0
Systematic review or meta-analysis
Clinical and translational gastroenterology · 2026 · PMID 42242200
INTRODUCTION: Gastrointestinal (GI) cancers account for a quarter of all cancers and one-third of cancer-related deaths worldwide. Novel diagnostic approaches are crucial to enhance early detection and improve patient outcomes. This review systematically identified and evaluated novel GI cancer detection approaches.
METHODS: A systematic review was conducted using PubMed, EMBASE, Scopus, and the Cochrane Library on December 11, 2024, and updated on June 2, 2025. Cohort studies and randomized controlled studies, pub…
Rank107.9
Systematic review or meta-analysisResult signal: null
Journal of surgical oncology · 2026 · PMID 42296400
BACKGROUND: This present systematic review and meta-analysis aims to compare overall survival (OS), disease-free survival (DFS), morbidity and mortality outcomes in patients undergoing colorectal first (CRf) versus liver first (Lf) resections with synchronous colorectal liver metastases.
METHODOLOGY: A literature search was performed in PubMed, Cochrane Central trials register, and Google Scholar databases. This was conducted in line with current PRISMA guidelines. 95% confidence intervals were calculated for the p…
Rank107.5
Systematic review or meta-analysisResult signal: harm
Critical reviews in oncology/hematology · 2026 · PMID 42069094
BACKGROUND: The therapeutic landscape of HCC has evolved, with ICI-based combinations progressively replacing TKI monotherapy as standard first-line treatment, although concerns remain regarding their safety profile.
METHODS: We performed a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing ICI-based combinations with TKI monotherapy as first-line treatment for advanced HCC. MEDLINE/PubMed, Scopus and the Cochrane Library were searched through December 1, 2025. The primary endpoint…
Rank107.3
Systematic review or meta-analysis
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2026 · PMID 42203603
BACKGROUND: Hepatocellular carcinoma (HCC) represents a major health burden, historically treated with tyrosine kinase inhibitors (TKIs). The advent of immune checkpoint inhibitors (ICIs) has reshaped treatments, with pivotal trials (IMbrave150 and HIMALAYA) establishing ICI-based combinations as first-line therapy. Traditional statistical metrics may not fully capture the robustness of trial outcomes. The Survival-Inferred Fragility Index (SIFI) quantifies trial stability as the minimum number of additional surviv…
Rank106.8
Systematic review or meta-analysis
World journal of surgery · 2026 · PMID 42281307
BACKGROUND: Laparoscopic liver resection (LLR) for posterosuperior (PS) segments remains technically challenging. Prior meta-analyses comparing LLR to open liver resection (OLR) often incorporated unmatched retrospective data, introducing severe selection bias, and predated recent randomized controlled trials (RCTs). This systematic review and meta-analysis evaluates the safety, short-term recovery, and oncological efficacy of LLR versus OLR specifically for parenchymal-preserving liver resection in PS segments (Co…
Rank106.4
Systematic review or meta-analysis
JHEP reports : innovation in hepatology · 2026 · PMID 42128139
BACKGROUND: The efficacy of second-line tyrosine kinase inhibitors (TKIs) after first-line immunotherapy-based (IO) treatment in advanced hepatocellular carcinoma (HCC) is not well-established.
METHODS: A systematic search was conducted to identify studies reporting outcomes with second-line TKIs after progression on first-line IO-based treatment. This reconstructed individual patient data (IPD) meta-analysis used survival data reconstructed from published Kaplan-Meier curves. Studies presenting or combining third-…
Rank106.3
Systematic review or meta-analysisResult signal: null
Journal of clinical gastroenterology · 2026 · PMID 42090574
BACKGROUND: Esophageal variceal bleeding (EVB) is a life-threatening complication of liver cirrhosis. Carvedilol, a nonselective β-blocker with α1-blocking properties, and endoscopic variceal ligation (EVL) are both recommended for prophylaxis, but their comparative performance remains uncertain.
METHODS: A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted, searching PubMed, Web of Science, and Embase to July 2025. Trials comparing carvedilol with EVL in adults with cirrhosis …
Rank106.2
Systematic review or meta-analysis
HPB : the official journal of the International Hepato Pancreato Biliary Association · 2026 · PMID 42185159
BACKGROUND: Large scale hepatectomy for primary or metastatic liver tumors may be limited by insufficient Future Liver Remnant (FLR). Strategies to enhance FLR hypertrophy include associating liver partition and portal vein ligation for staged hepatectomy (ALPPS), portal vein embolization (PVE), and Liver Venous Deprivation (LVD). Their comparative efficacy in the context of open hepatectomy remains unclear.
METHODS: A systematic review and meta-analysis of pairwise comparative studies was conducted (PubMed, Embase…
Rank106.0
Systematic review or meta-analysis
The Cochrane database of systematic reviews · 2026 · PMID 42713852
RATIONALE: Chronic hepatitis B is a global public health concern. It is caused by infection with the hepatitis B virus (HBV). The goal of treating chronic HBV infection is to prevent progression to chronic hepatitis, cirrhosis, hepatic decompensation, liver failure, hepatocellular carcinoma, and death. Individual studies have evaluated various immunomodulatory therapies with inconsistent results. Thymosin-ɑ1 is known to have antiviral effects; however, results of randomised clinical trials on the effects of thymosi…
Rank105.8
Systematic review or meta-analysis
Frontiers in immunology · 2026 · PMID 42327777
BACKGROUND: The therapeutic landscape of advanced hepatocellular carcinoma (HCC) has expanded beyond sorafenib, with multiple combination regimens now demonstrating improved outcomes. However, the absence of direct head-to-head comparisons complicates treatment selection in clinical practice.
METHODS: We performed a Bayesian network meta-analysis of phase III randomized controlled trials to compare the efficacy and safety of first-line treatments for patients with advanced HCC. Overall survival (OS), progression-fr…
Rank105.4
Systematic review or meta-analysis
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2026 · PMID 41490475
Bridging and downstaging are indications for locoregional therapy (LRT) in hepatocellular carcinoma (HCC) within the context of liver transplantation (LT). Stereotactic body radiation therapy (SBRT) is an emerging LRT modality in these settings. We conducted a systematic review and meta-analysis to assess the efficacy and safety of SBRT as bridging or downstaging therapy. A comprehensive search of PubMed, Embase, and Cochrane Library was performed through July 21, 2025. We included randomized and non-randomized stu…
Rank105.3
Systematic review or meta-analysis
European journal of cancer (Oxford, England : 1990) · 2026 · PMID 42330566
BACKGROUND: Evidence on the efficacy of percutaneous hepatic perfusion (PHP) in metastatic uveal melanoma (mUM) is largely derived from single-arm studies without comparators, complicating interpretation of treatment benefit, particularly for survival. This meta-analysis aimed to synthesize available evidence on the efficacy and safety of PHP in patients with mUM and compare outcomes with best alternative care (BAC).
MATERIAL AND METHODS: PubMed, Embase, Cochrane, and Web of Science were searched from database ince…
Rank104.8
Systematic review or meta-analysis
Hepatobiliary & pancreatic diseases international : HBPD INT · 2026 · PMID 42177126
BACKGROUND: Neuroendocrine liver metastases (NLMs) from gastroenteropancreatic neuroendocrine tumors (GEP-NETs) significantly impact morbidity and mortality. While surgical resection remains the standard treatment, radiofrequency ablation (RFA) has emerged as an alternative for unresectable cases. This systematic review compared the oncological outcomes of surgical resection and RFA.
DATA SOURCES: A systematic search of PubMed, Web of Science, and Scopus identified studies published between 2014 and 2025. Eligible …
Rank103.9
Systematic review or meta-analysis
Journal of surgical oncology · 2026 · PMID 42306995
Liver transplantation has emerged as a therapeutic option for highly selected patients with unresectable colorectal liver metastases (CRLM). This review evaluated oncologic and perioperative outcomes in 92 patients who underwent transplantation. One- and 3-year overall survival (OS) were 96.32% and 73.07%, respectively. Disease-free survival (DFS) was lower, with high rates of recurrence. Major complications occurred in 39.36%, and 90-day mortality was 1.03%. Further randomized studies are needed to better define t…
Rank103.8
Systematic review or meta-analysis
Critical reviews in oncology/hematology · 2026 · PMID 42250662
BACKGROUND: Immunotherapy-based regimens are standard first-line treatments for advanced hepatocellular carcinoma (HCC), yet integrated comparisons across efficacy, safety, and quality-of-life (QoL) outcomes remain limited. We performed a network meta-analysis (NMA) to identify the optimal treatment strategy.
METHODS: A literature search was conducted in PubMed, Embase, Cochrane Library, and Scopus to identify phase III randomized controlled trials (RCTs) evaluating immune checkpoint inhibitor (ICI)-based therapies…
Rank100.0
Systematic review or meta-analysisResult signal: benefit
Frontiers in immunology · 2026 · PMID 42529281
OBJECTIVE: This study aimed to evaluate the first-line treatment patterns and prognostic factors associated with survival in patients with driver gene-negative non-small cell lung cancer (NSCLC) and liver metastases, in order to identify the optimal treatment strategy.
METHODS: A Bayesian network meta-analysis was performed using R software (version 4.2.3) and RevMan (version 5.4) to systematically compare the efficacy of various first-line treatment regimens, including chemotherapy, immunotherapy, and combination …
Rank100.0
Systematic review or meta-analysis
Frontiers in endocrinology · 2026 · PMID 42312204
UNLABELLED: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve weight, glycemic control, and cardiometabolic risk factors, but randomized trials have not been powered to determine effects on advanced liver outcomes. We conducted a systematic review and exploratory meta-analysis of peer-reviewed comparative real-world cohort studies in adults with type 2 diabetes (T2D), emphasizing active-comparator designs, clinically advanced liver endpoints, and transparent limits of causal inference. PubMed/MEDLINE and…
Rank98.7
Randomized controlled trial
JHEP reports : innovation in hepatology · 2026 · PMID 41895663
BACKGROUND: The risk of hepatocellular carcinoma (HCC) and net benefit of surveillance can differ between patients with cirrhosis. We compared the benefits and harms of HCC surveillance across risk strata in patients with cirrhosis.
METHODS: We leveraged a cohort of patients with cirrhosis from a pragmatic randomized controlled trial of HCC surveillance outreach enrolled between March 2018 and April 2021. Patients were stratified into low-, intermediate-, and high-risk categories based on published thresholds for t…
Rank98.3
Randomized controlled trial
Cancer prevention research (Philadelphia, Pa.) · 2026 · PMID 42310898
UNLABELLED: Hepatocellular carcinoma (HCC) is a lethal cancer with an increasing burden. Few clinical trials have evaluated preventive strategies for HCC in high-risk patients with liver cirrhosis. Observational studies show that statins are associated with a reduced HCC risk although a causal link has yet to be established. This multicenter randomized double-blinded, placebo-controlled phase II trial of 40 mg/day oral simvastatin to reduce the likelihood of hepatocarcinogenesis was conducted at four sites in the U…
Rank98.1
Randomized controlled trial
The Lancet. Oncology · 2026 · PMID 42636832
BACKGROUND: Transarterial chemoembolisation (TACE), a standard treatment for embolisation-eligible hepatocellular carcinoma (HCC), induces tumour immune responses. Single tremelimumab regular interval durvalumab (STRIDE) is a standard treatment in advanced HCC. In this phase 3 trial, we assessed the efficacy and safety of STRIDE, with or without lenvatinib, plus TACE, in participants with embolisation-eligible HCC.
METHODS: EMERALD-3 is a phase 3, randomised, open-label, sponsor-blinded study, conducted at 177 medi…
Rank97.7
Randomized controlled trial
Maternal & child nutrition · 2026 · PMID 42169402
This study investigated the role of early-life nutrition supplementation in regulating the development of hypothalamic-pituitary-adrenal (HPA) axis activity, as evidenced by hair cortisol concentration (HCC), in the iLiNS-DYAD randomized controlled trial in Ghana. Pregnant women were randomized to one of three conditions: (1) iron and folic acid (IFA) during pregnancy and placebo 0-6 mo postpartum; (2) multiple micronutrients (MMN) during pregnancy and 0-6 mo postpartum; or (3) small-quantity lipid-based nutrient s…
Rank97.7
Randomized controlled trial
World journal of pediatrics : WJP · 2026 · PMID 42449025
BACKGROUND: Oral propranolol, with or without corticosteroids, has been shown to benefit diffuse infantile hepatic haemangioma (IHH); randomized trial evidence is lacking. We aimed to evaluate the efficacy and safety of propranolol monotherapy versus propranolol plus prednisone for the treatment of problematic IHHs to determine whether oral prednisone provided an added benefit to propranolol.
METHODS: We conducted an open-label, multicenter, randomized controlled trial across six referral centers in China from July…
Safety And Adverse Effects291 records
Rank110.0
Systematic review or meta-analysis
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2026 · PMID 42285810
BACKGROUND AND AIMS: Statins have been proposed as hepatoprotective agents in chronic liver disease (CLD); however, evidence from existing systematic reviews-including observational studies and clinical trials-is inconsistent and affected by substantial overlap. We conducted an umbrella review to synthesize the available evidence on the associations between statin use and hepatological outcomes in CLD patients, while addressing study overlap.
DESIGN: PubMed, EMBASE, and Cochrane Library were searched up to Septembe…
Rank107.9
Systematic review or meta-analysisResult signal: null
Journal of neurology · 2026 · PMID 42251157
BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment with significant improvements in survival rates. With the increase in ICI use in the clinical setting, several case reports and series have described neurological adverse events associated with it. We conducted this systematic review and meta-analysis to estimate the incidence of neurological adverse events among ICI clinical trials.
METHODS: We searched PubMed, Embase, Scopus, and the Cochrane Central Register of Controlled Trials…
Rank107.8
Systematic review or meta-analysis
Frontiers in pharmacology · 2026 · PMID 42358365
BACKGROUND: With the rapid introduction of immune checkpoint inhibitors (ICIs) for advanced hepatocellular carcinoma (HCC), optimal treatment sequencing remains unclear. Lacking direct comparisons, we aimed to evaluate the efficacy and safety of systemic therapies across first- and second-line settings.
METHODS: A frequentist network meta-analysis (PROSPERO: CRD420261296427) was performed using phase III RCTs from PubMed, Embase, Cochrane, and Web of Science (up to January 2026) evaluating systemic HCC therapies. T…
Rank107.0
Systematic review or meta-analysis
Medicine · 2026 · PMID 42299577
BACKGROUND: Beyond surgical intervention, hepatocellular carcinoma is mainly treated with 3 main approaches: transarterial chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC) as local treatment, immune checkpoint inhibitors (ICIs), and tyrosine kinase inhibitors (TKIs). Up to now, clinical experts have not reached a consistent consensus on how to reasonably select combination therapy. Therefore, we performed this research to contrast the clinical outcomes of local treatment plus ICIs and TKIs …
Rank106.8
Systematic review or meta-analysis
World journal of surgery · 2026 · PMID 42281307
BACKGROUND: Laparoscopic liver resection (LLR) for posterosuperior (PS) segments remains technically challenging. Prior meta-analyses comparing LLR to open liver resection (OLR) often incorporated unmatched retrospective data, introducing severe selection bias, and predated recent randomized controlled trials (RCTs). This systematic review and meta-analysis evaluates the safety, short-term recovery, and oncological efficacy of LLR versus OLR specifically for parenchymal-preserving liver resection in PS segments (Co…
Rank106.3
Systematic review or meta-analysisResult signal: null
Journal of clinical gastroenterology · 2026 · PMID 42090574
BACKGROUND: Esophageal variceal bleeding (EVB) is a life-threatening complication of liver cirrhosis. Carvedilol, a nonselective β-blocker with α1-blocking properties, and endoscopic variceal ligation (EVL) are both recommended for prophylaxis, but their comparative performance remains uncertain.
METHODS: A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted, searching PubMed, Web of Science, and Embase to July 2025. Trials comparing carvedilol with EVL in adults with cirrhosis …
Rank106.2
Systematic review or meta-analysis
HPB : the official journal of the International Hepato Pancreato Biliary Association · 2026 · PMID 42185159
BACKGROUND: Large scale hepatectomy for primary or metastatic liver tumors may be limited by insufficient Future Liver Remnant (FLR). Strategies to enhance FLR hypertrophy include associating liver partition and portal vein ligation for staged hepatectomy (ALPPS), portal vein embolization (PVE), and Liver Venous Deprivation (LVD). Their comparative efficacy in the context of open hepatectomy remains unclear.
METHODS: A systematic review and meta-analysis of pairwise comparative studies was conducted (PubMed, Embase…
Rank105.8
Systematic review or meta-analysis
Cancer research and treatment · 2026 · PMID 40808533
PURPOSE: Lymph node metastasis (LNM) of hepatocellular carcinoma (HCC) carries a poor prognosis; however, no standard treatment has been established. Radiotherapy (RT) has demonstrated favorable tumor response, with the advantage of being less affected by anatomical hindrances.
MATERIALS AND METHODS: Databases were searched up to April 2024. The inclusion criteria were ≥ 5 patients with HCC LNM, studies that performed external RT, and reporting survival or response rate (RR). The main effect measures are pooled 1- …
Rank105.8
Systematic review or meta-analysis
Frontiers in immunology · 2026 · PMID 42327777
BACKGROUND: The therapeutic landscape of advanced hepatocellular carcinoma (HCC) has expanded beyond sorafenib, with multiple combination regimens now demonstrating improved outcomes. However, the absence of direct head-to-head comparisons complicates treatment selection in clinical practice.
METHODS: We performed a Bayesian network meta-analysis of phase III randomized controlled trials to compare the efficacy and safety of first-line treatments for patients with advanced HCC. Overall survival (OS), progression-fr…
Rank105.3
Systematic review or meta-analysis
European journal of cancer (Oxford, England : 1990) · 2026 · PMID 42330566
BACKGROUND: Evidence on the efficacy of percutaneous hepatic perfusion (PHP) in metastatic uveal melanoma (mUM) is largely derived from single-arm studies without comparators, complicating interpretation of treatment benefit, particularly for survival. This meta-analysis aimed to synthesize available evidence on the efficacy and safety of PHP in patients with mUM and compare outcomes with best alternative care (BAC).
MATERIAL AND METHODS: PubMed, Embase, Cochrane, and Web of Science were searched from database ince…
Rank105.0
Systematic review or meta-analysis
Frontiers in oncology · 2026 · PMID 42488105
OBJECTIVE: This meta-analysis was conducted to compare the clinical efficacy and safety of image-guided radiofrequency ablation (RFA) versus microwave ablation (MWA) for the treatment of small to medium-sized hepatocellular carcinoma (HCC).
METHODS: A systematic search of four English databases (PubMed, Web of Science, Cochrane Library, EMBASE) was performed up to January 8, 2026. Randomized controlled trials (RCTs) and cohort studies comparing RFA and MWA for HCC were included. The Cochrane Risk of Bias tool (RoB …
Rank104.8
Systematic review or meta-analysis
Hepatobiliary & pancreatic diseases international : HBPD INT · 2026 · PMID 42177126
BACKGROUND: Neuroendocrine liver metastases (NLMs) from gastroenteropancreatic neuroendocrine tumors (GEP-NETs) significantly impact morbidity and mortality. While surgical resection remains the standard treatment, radiofrequency ablation (RFA) has emerged as an alternative for unresectable cases. This systematic review compared the oncological outcomes of surgical resection and RFA.
DATA SOURCES: A systematic search of PubMed, Web of Science, and Scopus identified studies published between 2014 and 2025. Eligible …
Rank104.6
Systematic review or meta-analysis
Journal of pediatric surgery · 2026 · PMID 41833711
INTRODUCTION: Despite the broader adoption of minimally invasive liver surgery (MILS) for adults, its application in the pediatric population has been mainly documented in single-center reports. We aimed to summarize the current state of evidence of MILS in children.
METHODS: We systematically reviewed PubMed, Scopus, Web of Science, and Cochrane Library databases according to the PRISMA statement for children (<18 years) undergoing MILS (end-of-search date: 03/03/2024). The National Cancer Database (NCDB) was quer…
Rank103.8
Systematic review or meta-analysisResult signal: null
Cancers · 2026 · PMID 42352517
(1) Background: This systematic literature review (SLR) and meta-analysis evaluated the comparative clinical effectiveness and safety of transarterial radioembolization (TARE) versus transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC). (2) Methods: Eligible studies were identified through an SLR following PRISMA guidelines using a predefined PICOS framework. PubMed and Embase were searched (2015-2025) for randomized controlled trials (RCTs) and observational studies comparing TARE…
Rank103.6
Systematic review or meta-analysisResult signal: benefit
Cancers · 2026 · PMID 42449661
Background: Hepatocellular carcinoma (HCC) represents the most common primary liver cancer and a significant cause of global cancer-related mortality, with the majority of patients diagnosed at advanced or unresectable stages. Historically, tyrosine kinase inhibitor (TKI) monotherapies such as sorafenib and lenvatinib served as the primary systemic standard of care. However, the emergence of immune checkpoint inhibitor (ICPI)-based combinations has significantly transformed the treatment landscape. We aim to perfor…
Rank103.5
Systematic review or meta-analysis
EClinicalMedicine · 2026 · PMID 42382132
BACKGROUND: This is an updated component network meta-analysis to evaluate efficacy and safety of various therapeutic approaches and their combinations for small hepatocellular carcinoma (SHCC) following PRISMA 2020 guideline.
METHODS: We screened two previously published meta-analyses on this topic, and searched PubMed, Embase, and the Cochrane Library from 1 January 2021 to 12 March 2026 for randomized controlled trials (RCTs) focusing on treatments of SHCC. We compared the efficacy and safety of surgical resecti…
Rank103.3
Systematic review or meta-analysis
Translational cancer research · 2026 · PMID 42591416
BACKGROUND: Immune checkpoint inhibitor (ICI) plus targeted therapy has revolutionized the treatment paradigm for unresectable hepatocellular carcinoma (HCC). However, evidence regarding liver toxicity associated with ICI plus targeted therapy remains limited, particularly with respect to fatal adverse events (FAEs) and serious adverse events (SAEs). Therefore, this meta-analysis aimed to systematically compare the hepatotoxicity profiles between ICI plus targeted therapy and tyrosine kinase inhibitor (TKI) monothe…
Rank102.8
Systematic review or meta-analysis
ESMO gastrointestinal oncology · 2026 · PMID 42582959
BACKGROUND: Transarterial chemoembolization (TACE) is the standard of care for intermediate-stage unresectable hepatocellular carcinoma (HCC), but progression-free survival (PFS) with TACE alone remains limited. Recent randomized clinical trials have evaluated the addition of immune checkpoint inhibitors (ICIs) to TACE. We conducted a meta-analysis of randomized trials to assess the efficacy and safety of TACE plus ICIs versus TACE alone in unresectable HCC.
MATERIALS AND METHODS: A systematic search of PubMed, Emb…
Rank100.0
Systematic review or meta-analysis
Frontiers in oncology · 2026 · PMID 42326328
BACKGROUND: Multiple primary tumours (MPT) involving the head and neck represent a growing and insufficiently systematised challenge in contemporary head and neck oncology. Patients with head and neck squamous cell carcinoma (HNSCC) face a cumulative risk of 2-4% per year of developing a second primary malignancy, driven by field cancerisation, persistent exposure to tobacco and alcohol, and improved survival after multimodality treatment.
METHODS: Observational analysis of patients with ICD-10 C00-C14 and C30-C32 …
Rank100.0
Systematic review or meta-analysis
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2026 · PMID 42250592
Nicotine, the principal addictive component of tobacco smoke, has traditionally been regarded as non-carcinogenic. However, accumulating evidence over the past two decades has established nicotine as a significant tumor promoter facilitating cancer initiation, progression, metastasis, and therapeutic resistance. This systematic review examines the molecular mechanisms by which nicotine modulates p53-mediated signaling pathways across four major cancer types: lung, gastric, liver, and cervical cancer. In lung cancer…
Rank100.0
Systematic review or meta-analysis
Frontiers in medicine · 2026 · PMID 42359071
BACKGROUND: Epigallocatechin-3-gallate (EGCG) constitutes the main component of tea polyphenols found in tea leaves and has been found to have a positive therapeutic effect on various digestive system diseases. However, no systematic review has been conducted on the research progress and mechanisms of EGCG in relation to digestive system diseases, an its toxicity.
METHODS: We conducted a comprehensive literature search for preclinical studies from the inception of each database to 28th September 2025, including Emb…
Rank98.3
Randomized controlled trial
Cancer prevention research (Philadelphia, Pa.) · 2026 · PMID 42310898
UNLABELLED: Hepatocellular carcinoma (HCC) is a lethal cancer with an increasing burden. Few clinical trials have evaluated preventive strategies for HCC in high-risk patients with liver cirrhosis. Observational studies show that statins are associated with a reduced HCC risk although a causal link has yet to be established. This multicenter randomized double-blinded, placebo-controlled phase II trial of 40 mg/day oral simvastatin to reduce the likelihood of hepatocarcinogenesis was conducted at four sites in the U…
Rank98.2
Systematic review or meta-analysis
Medicine · 2026 · PMID 42536554
BACKGROUND: This study aimed to summarize and grade the existing evidence on continuous hepatic artery infusion chemotherapy (HAIC) arterial drug administration and catheter care, providing evidence-based guidance for clinical nursing decisions.
METHODS: Using the "6S" pyramid model, We searched 10 electronic resources (UpToDate, Joanna Briggs Institute [JBI], Cochrane Library, Web of Science, Embase, PubMed, EBSCOhost Research Platform, China National Knowledge Infrastructure, Wanfang, and SinoMed) and 5 professio…
Rank98.0
Systematic review or meta-analysis
Cancers · 2026 · PMID 42512372
Background/Objectives: Intraoperative ultrasound (IOUS) has become an integral component of modern hepatic oncology surgery, providing real-time imaging guidance during liver resections for hepatocellular carcinoma, colorectal liver metastases, and other primary or secondary hepatic malignancies. Despite substantial improvements in preoperative imaging modalities, occult lesions, disappearing metastases after chemotherapy, and complex vascular relationships continue to represent major intraoperative challenges. Thi…
Rank96.7
Randomized controlled trial
The lancet. Gastroenterology & hepatology · 2026 · PMID 42330996
BACKGROUND: Patients with unresectable hepatocellular carcinoma have a poor prognosis and treatments with long-term benefits are needed. Anti-PD-L1 or anti-PD-1 plus anti-VEGF or anti-CTLA-4 double combinations are validated, first-line, systemic immunotherapies. We report the preplanned phase 2 results of the phase 2-3 PRODIGE 81-FFCD 2101-TRIPLET-HCC trial investigating the survival outcomes and safety profile of a triple combination of atezolizumab, bevacizumab, and ipilimumab in a first-line setting.
METHODS: T…
Treatments That Failed Clinical Trials64 records
Rank101.3
Randomized controlled trialResult signal: null
JAMA · 2024 · PMID 39158894
IMPORTANCE: Tranexamic acid reduces bleeding and blood transfusion in many types of surgery, but its effect in patients undergoing liver resection for a cancer-related indication remains unclear.
OBJECTIVE: To determine whether tranexamic acid reduces red blood cell transfusion within 7 days of liver resection.
DESIGN, SETTING, AND PARTICIPANTS: Multicenter randomized clinical trial of tranexamic acid vs placebo conducted from December 1, 2014, to November 8, 2022, at 10 hepatopancreaticobiliary sites in Canada and…
Rank98.1
Randomized controlled trialResult signal: mixed
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025 · PMID 40554738
PURPOSE: We conducted a randomized controlled trial (SURF-RCT) to evaluate the efficacy of surgery versus radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC). Simultaneously, eligible patients who dissented from random assignment were enrolled in a nonrandomized prospective observational trial (SURF-Cohort). We aimed to report the final analyses of overall survival (OS) and updated recurrence-free survival (RFS) in the SURF-RCT and SURF-Cohort trials.
METHODS: The trials were conducted in 49 institutio…
Rank97.7
Randomized controlled trialResult signal: null
La Radiologia medica · 2024 · PMID 39495436
PURPOSE: This multicenter prospective study aims to compare transradial access versus transfemoral access in conventional transarterial chemoembolization (c-TACE) procedures, focusing on operators radiations exposure, patients comfort, technical success and vascular access complications.
MATERIALS AND METHODS: Patients were affected by hepatocellularcarcinoma (HCC) in intermediate stage or previous stages unfit for ablation and/or surgery; they were randomized into two groups according to arterial access site (Grou…
Rank97.5
Randomized controlled trialResult signal: benefit
Cancer immunology, immunotherapy : CII · 2026 · PMID 41591582
BACKGROUND: Most adjuvant therapies for hepatocellular carcinoma (HCC) have failed except for autologous cytokine-induced killer (CIK) therapy, which prolonged recurrence-free survival (RFS) in a previously reported randomized controlled trial (RCT) and real-world data (RWD).
METHODS: This study aimed to assess the long-term outcomes of adjuvant CIK therapy using both an extended follow-up of the original RCT and a retrospective cohort study. An extended follow-up analysis of the RCT included 226 patients (114 in t…
Rank97.5
Randomized controlled trialResult signal: null
Anaesthesia · 2025 · PMID 39776101
BACKGROUND: While evidence from preclinical and observational cohort studies have suggested potential disparities in tumour behaviour associated with the choice of intra-operative anaesthetics, clinical evidence of tumour recurrence and metastasis remains inconclusive. We aimed to compare the impact of intra-operative anaesthesia on oncologic outcomes following hepatectomy for hepatocellular carcinoma.
METHODS: Adult patients scheduled for elective hepatectomy for hepatocellular carcinoma were assigned randomly (1:…
Rank97.3
Randomized controlled trialResult signal: null
The British journal of surgery · 2025 · PMID 39991838
BACKGROUND: Venous thrombosis represents a significant complication after deceased-donor liver transplantation, yet there are currently no established protocols for thromboprophylaxis after deceased-donor liver transplantation. The aim of this study was to evaluate the efficacy and safety of prophylactic anticoagulation in patients undergoing deceased-donor liver transplantation.
METHODS: A dual-centre RCT of patients assigned to receive either enoxaparin or normal saline after liver transplantation was conducted. …
Rank97.0
Randomized controlled trialCorrection flagged
The Lancet. Oncology · 2025 · PMID 39848272
BACKGROUND: For patients with small-size colorectal liver metastases, growing evidence suggests thermal ablation to be associated with fewer adverse events and faster recovery than resection while also challenging resection in terms of local control and overall survival. This study assessed the potential non-inferiority of thermal ablation compared with surgical resection in patients with small-size resectable colorectal liver metastases.
METHODS: Adult patients (aged ≥18 years) from 14 centres in the Netherlands, …
Rank97.0
Randomized controlled trialResult signal: null
European journal of medical research · 2025 · PMID 41163129
BACKGROUND AND AIMS: Donafenib, a deuterium-modified sorafenib derivative, has improved survival outcomes in patients with advanced hepatocellular carcinoma (HCC). This study aimed to investigate the treatment-related adverse events and their associations with overall survival (OS) and time to progression (TTP) in patients with advanced HCC treated with donafenib.
METHODS: In this retrospective analysis, data from 334 patients with unresectable or metastatic HCC who had a Child-Pugh liver function score ≤ 7 and had…
Rank96.7
Randomized controlled trialResult signal: mixed
Surgical endoscopy · 2025 · PMID 39994051
BACKGROUND: Low muscle mass is negatively associated with survival in patients undergoing surgery for colorectal cancer. Current evidence is limited regarding whether the surgical approach for liver resection of colorectal metastasis impacts postoperative changes in body composition and whether preoperative body composition can impact complication rate and survival.
METHOD: This study included patients previously included in the randomized OSLO-COMET trail where patients was allocated to laparoscopic or open liver …
Rank96.6
Randomized controlled trialResult signal: null
Scientific reports · 2025 · PMID 41286133
To investigate the effectiveness of TACE in combination with anlotinib and sintilimab in the treatment of unresectable hepatocellular carcinoma. A total of 210 patients with primary unresectable hepatocellular carcinoma (PAC) in our hospital from January 2020 to December 2023 were selected as the study subjects, and they were divided into two groups of 105 cases each by the envelope method using sequentially numbered, opaque sealed envelopes containing computer-generated random allocations. The control group was tr…
Rank96.4
Randomized controlled trialResult signal: null
European journal of cancer (Oxford, England : 1990) · 2026 · PMID 41833569
BACKGROUND: Stereotactic body radiotherapy (SBRT) has been proven effective for treating small hepatocellular carcinoma (sHCC); however, the comparative efficacy of SBRT and surgical resection remains unknown. This analysis aims to compare the outcomes of SBRT and resection in treating recurrent sHCC.
METHODS: Two randomized controlled trials enrolled recurrent sHCC undergoing resection (NCT01833286) or SBRT (NCT04047173). Patients with single recurrent HCC ≤ 5 cm were included in this study. The primary endpoint w…
Rank96.3
Randomized controlled trialResult signal: mixed
Scandinavian journal of gastroenterology · 2024 · PMID 39154241
OBJECTIVE: This study compared the efficacy and safety of the transarterial chemoembolization with CalliSpheres® drug-eluting beads loading with doxorubicin (DEB-TACE) versus conventional lipiodol (cTACE) in patients with unresectable hepatocellular carcinoma (HCC).
METHODS: A randomized controlled trial (RCT) was conducted with 144 patients, who were randomly assigned to receive either DEB-TACE with doxorubicin-loaded CalliSpheres® microspheres or cTACE with doxorubicin-lipiodol emulsion. Patients were followed up…
Rank96.0
Randomized controlled trial
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025 · PMID 40935954
OBJECTIVE: This study aimed to explore the effect of nursing intervention based on the broaden-and-build theory on the psychosocial adaptability of patients with minimally invasive ablation of liver cancer.
METHOD: A total of 100 patients with liver cancer undergoing minimally invasive ablation were selected and randomly divided into two groups. The control group consisted of 50 patients who received routine nursing intervention and Health education. The intervention group consisted of 50 patients who received nurs…
Rank96.0
Randomized controlled trialResult signal: null
Cardiovascular and interventional radiology · 2026 · PMID 41572025
PURPOSE: To compare the patency outcomes and safety profile between the modified TR Band and the PreludeSYNC DISTAL (PSD) for hemostasis following distal transradial access (dTRA) for transarterial chemoembolization (TACE).
METHODS: This prospective randomized trial enrolled 104 participants undergoing TACE via dTRA (143 procedures, all performed using a 4-Fr catheter. Participants achieved hemostasis with either the modified TR Band (n = 74) or PSD (n = 69). The primary endpoint was the incidence of radial artery …
Rank95.9
Randomized controlled trialResult signal: null
The Kaohsiung journal of medical sciences · 2026 · PMID 40888625
Hepatocellular carcinoma (HCC) surveillance with semi-annual ultrasound (US) is recommended for high-risk patients. This study investigates the impact of hepatobiliary abbreviated magnetic resonance imaging (AMRI) performed annually on the recommended US surveillance. Patients with compensated liver cirrhosis at regular HCC surveillance using US and alpha-fetoprotein, with adequate renal function and without HCC diagnosis, were enrolled. Patients were randomized into add-on hepatobiliary AMRI and continuous US surv…
Rank95.9
Randomized controlled trial
Journal of clinical anesthesia · 2024 · PMID 38851003
STUDY OBJECTIVE: To determine if single-injection bilateral posterior quadratus lumborum block (QLB) with ropivacaine would improve postoperative analgesia in the first 24 h after laparoscopic hepatectomy, compared with 0.9% saline.
DESIGN: Prospective, double blinded, randomized controlled trial.
SETTING: A single tertiary care center from November 2021 and January 2023.
PATIENTS: A total of 94 patients scheduled to undergo laparoscopic hepatectomy due to hepatocellular carcinoma.
INTERVENTIONS: Ninety-four patien…
Rank95.9
Randomized controlled trialResult signal: mixed
International journal of surgery (London, England) · 2024 · PMID 38377058
PURPOSE: Hepatocellular carcinoma (HCC) is a significant health concern, and the complexity of liver anatomy poses challenges in conveying radiologic findings and surgical plans to patients. This study aimed to evaluate the impact of a virtual reality (VR) education program on anxiety and knowledge in HCC patients undergoing hepatic resection.
METHOD: From 1 January 2022 to 28 February 2023, 88 patients were enrolled in a randomized controlled trial, divided into the VR group ( n =44) and the control group ( n =44)…
Rank95.9
Randomized controlled trialResult signal: mixed
Hepatobiliary & pancreatic diseases international : HBPD INT · 2026 · PMID 41390276
BACKGROUND: Successful liver resection in oncologic surgery depends on safety, precision, and efficacy, all of which require a thorough understanding of liver anatomy. Contrast-enhanced computed tomography (CT)-generated three-dimensional (3D) models have been proposed as a valuable tool to enhance this understanding. However, a systematic comparison of different display modalities across professional groups has not yet been performed.
METHODS: In this prospective, monocentric randomized trial, we compared high-res…
Rank95.9
Randomized controlled trialResult signal: null
European journal of cancer (Oxford, England : 1990) · 2025 · PMID 39644535
BACKGROUND: Hepatic artery infusion (HAI) chemotherapy, particularly with floxuridine (FUDR), has previously shown effectiveness in improving recurrence-free survival (RFS) in colorectal cancer (CRC) patients with colorectal liver metastases (CRLM). Nonetheless, its adjuvant use alongside modern systemic chemotherapy remains unevaluated.
PATIENTS AND METHODS: The HARVEST trial is an open-label, randomized, controlled study conducted from May 2018 to August 2021. CRC patients with resectable primary tumors and CRLM …
Rank95.8
Randomized controlled trialResult signal: null
Current medical science · 2024 · PMID 39565503
OBJECTIVE: This prospective randomized controlled study was conducted to evaluate the safety and efficacy of the Pringle hepatic hilar occlusion with a bulldog clamp in laparoscopic liver resection.
METHODS: From March 1, 2020 to July 31, 2021, 80 patients were enrolled, including 40 undergoing intraperitoneal Pringle maneuver (IPM) and 40 extraperitoneal Pringle maneuver (EPM). The observation indices included basic preoperative clinical characteristics and intraoperative and postoperative liver function indices.
…
Rank95.8
Randomized controlled trialResult signal: null
Medicine · 2025 · PMID 39993117
BACKGROUND: This study investigated the application of a composite warming strategy in the perioperative care of patients who underwent open hepatectomy for liver cancer. The clinical efficacy of the composite warming strategy was observed and analyzed, and the factors causing hypothermia were discussed.
METHODS: From January 2020 to December 2021, 80 patients were selected for the study. The control group adopted perioperative forced-air warming measures, while the experimental group implemented a composite warmin…
Rank95.7
Randomized controlled trialResult signal: null
PLoS medicine · 2024 · PMID 38728364
BACKGROUND: It remains unclear whether intensification of the chemotherapy backbone in tandem with an anti-EGFR can confer superior clinical outcomes in a cohort of RAS/BRAF wild-type colorectal cancer (CRC) patients with initially unresectable colorectal liver metastases (CRLM). To that end, we sought to comparatively evaluate the efficacy and safety of cetuximab plus FOLFOXIRI (triplet arm) versus cetuximab plus FOLFOX (doublet arm) as a conversion regimen (i.e., unresectable to resectable) in CRC patients with u…
Rank95.6
Randomized controlled trialResult signal: harm
Experimental oncology · 2026 · PMID 41788066
UNLABELLED: The aim of the study was to evaluate the impact of quadratus lumborum block (QL block) compared to epidural analgesia (EA) on the postoperative liver functional recovery, coagulation profile, metabolic changes, and hemodynamic stability in patients undergoing liver resection for colorectal liver metastases.
MATERIALS AND METHODS: This prospective randomized study included 64 patients allocated in a 1:1 ratio to EA or QL block groups. 56 patients (28 per group) were included in the final analysis. The pr…
Rank95.4
Randomized controlled trialResult signal: null
British journal of cancer · 2025 · PMID 40263401
BACKGROUND: We have previously reported that vitamin K dosing augments the anticancer effects of sorafenib by suppressing levels of des-γ-carboxy prothrombin, a known tumor growth and angiogenesis factor produced in HCC under sorafenib-induced ischemia. Herein, we aimed to establish whether vitamin K dosing could afford a similar anticancer effect when combined with transarterial chemoembolization (TACE).
METHODS: We performed a randomized controlled trial, assigning patients with unresectable HCC (1:1) to TACE + v…
Rank95.4
Randomized controlled trialResult signal: null
RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin · 2024 · PMID 38065541
PURPOSE: To compare the therapeutic response and clinical outcome of CT-guided percutaneous microwave (MWA) and radiofrequency ablation (RFA) for the treatment of small- and medium-sized HCC.
MATERIALS AND METHODS: In this prospective trial, 50 patients with HCC were randomly assigned to MWA or RFA treatment. MRI was performed 24 h before and after ablation and subsequently in 3-month intervals. Ablation volumes, ablation durations, adverse events (AE), technique efficacy, technical success, local tumor progression…
i
Research information noticeAlexandria organizes PubMed-indexed literature. PubMed inclusion does not establish accuracy, endorsement, clinical applicability, or treatment suitability. Automated extraction can contain errors or omissions. This page is not medical advice.